[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_95":96},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","mxri2xs43zft2cjf2wvdcbcjy","revision",2,"title","FT 13299（Biotechnology Portfolio, Series 71）招股说明书","originalTitle","FT 13299 (0002147133) (Filer)","summary","First Trust Portfolios L.P. 发起的 FT 13299（Biotechnology Portfolio, Series 71）于2026年10月30日初始存入，持有25只医疗保健公司普通股，目标是实现高于平均水平的资本增值。","reason","source",{"_11":85,"_86":87,"_88":89,"_90":57,"_91":92,"_93":94},"links",{"_82":83,"_63":84},"publishedAt","2026-10-30T17:20:19.000Z","discoveredAt","2026-10-30T18:24:29.473Z","timelineAt","category","ai-products","tags",[80,81],"stockSymbols",[],"score",21,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fsY0rZxAVK1M",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","6108d90f-0100-409d-8b8e-e32c49d97164","FT 13299生物科技投资组合招股说明书存档",{"_72":73,"_15":74},"zh","

Registration No. 333-298553

1940 Act No. 811-05903

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Amendment No. 1 to Form S-6

FOR REGISTRATION UNDER THE SECURITIES ACT OF 1933 OF SECURITIES OF UNIT INVESTMENT\nTRUSTS REGISTERED ON FORM N-8B-2

A.Exact name of trust:

FT 13299

B.Name of depositor:

FIRST TRUST PORTFOLIOS L.P.

C.Complete address of depositor’s principal executive offices:

120 East Liberty Drive

Suite 400

Wheaton, Illinois 60187

D.Name and complete address of agents for service:

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	Copy to:

JAMES A. BOWEN	ERIC F. FESS
c/o First Trust Portfolios L.P.	c/o Chapman and Cutler LLP
120 East Liberty Drive	320 South Canal Street
Suite 400	27th Floor
Wheaton, Illinois 60187	Chicago, Illinois 60606

E.Title and Amount of Securities Being Registered:

An indefinite number of Units pursuant to Rule 24f-2 promulgated under the Investment\nCompany Act of 1940, as amended.

F.Approximate date of proposed sale to public:

As soon as practicable after the effective date of the Registration Statement.

|X|

Check box if it is proposed that this filing will become effective on October\n30, 2026 at 2:00 p.m. pursuant to Rule 487.

________________________________

Biotechnology\nPortfolio, Series 71

FT\n13299

FT\n13299 is a series of a unit investment trust, the FT Series. FT 13299 consists of a single portfolio known as Biotechnology Portfolio,\nSeries 71 (the “Trust”). The Trust invests in a diversified portfolio of common stocks (“Securities”) issued by\nbiotechnology companies and pharmaceutical companies actively participating in the biotechnology industry. The Trust seeks above-average\ncapital appreciation.

THE\nSECURITIES AND EXCHANGE COMMISSION (“SEC”) HAS NOT APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY\nOF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

$\"\"$

800–621–1675

The\ndate of this prospectus is October 30, 2026

\n \n \n

Table of Contents

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

Summary of Essential Information			3
Fee Table			4
Report of Independent Registered Public Accounting Firm			5
Statement of Net Assets			6
Schedule of Investments			7
The FT Series			9
Portfolio			10
Risk Factors			10
Public Offering			13
Distribution of Units			15
The Sponsor’s Profits			17
The Secondary Market			17
How We Purchase Units			17
Expenses and Charges			17
Tax Status			18
Retirement Plans			20
Rights of Unit Holders			20
Income and Capital Distributions			21
Redeeming Your Units			21
Removing Securities from the Trust			22
Amending or Terminating the Indenture			23
Information on the Sponsor and Trustee			24
Other Information			25

\n \n \n

Summary of Essential Information\n (Unaudited)

Summary of Essential Information

Biotechnology\nPortfolio, Series 71
\nFT 13299

At the Opening of Business on the Initial\nDate of Deposit—October 30, 2026

\tSponsor:\tFirst Trust Portfolios L.P.
\n\tTrustee:\tThe Bank of New York Mellon

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

Initial Number of Units (1)\t		16,084
Fractional Undivided Interest in the Trust per Unit (1)\t		1/16,084
Public Offering Price:
Public Offering Price per Unit (2)\t\t	$	10.000
Less Initial Sales Charge per Unit (3)\t		(.000	)
Aggregate Offering Price Evaluation of Securities per Unit (4)\t		10.000
Less Deferred Sales Charge per Unit (3)\t\t		(.225	)
Redemption Price per Unit (5)\t\t		9.775
Less Creation and Development Fee per Unit (3)(5)\t\t		(.050	)
Less Organization Costs per Unit (5)\t\t		(.051	)
Net Asset Value per Unit\t\t	$	9.674
Cash CUSIP Number\t		30346Y 329
Reinvestment CUSIP Number\t\t		30346Y\n337
Fee Account Cash CUSIP Number\t		30346Y\n345
Fee Account Reinvestment CUSIP Number\t\t		30346Y\n352
Ticker Symbol\t		FVFKVX

\n \n \n \n \n \n \n \n \n \n \n \n \n

First Settlement Date\t	November 2, 2026
Mandatory Termination Date (6)\t	October 30, 2028
Income Account Distribution Record Date\t	Tenth day of each June and December, commencing December 10, 2026.
Income Account Distribution Date (7)\t	Twenty-fifth day of each June and December, commencing December 25, 2026.

(1)

As of the Evaluation Time (defined below in footnote 4) on the Initial Date of Deposit, we may adjust\nthe number of Units of the Trust so that the Public Offering Price per Unit will equal approximately $10.00. If we make such an adjustment,\nthe fractional undivided interest per Unit will vary from the amount indicated above.

(2)

The Public Offering Price shown above reflects the value of the Securities on the business day prior to\nthe Initial Date of Deposit. No investor will purchase Units at this price. The price you pay for your Units will be based on their valuation\nat the Evaluation Time on the date you purchase your Units. On the Initial Date of Deposit, the Public Offering Price per Unit will not\ninclude any accumulated dividends on the Securities. After this date, a pro rata share of any accumulated dividends on the Securities\nwill be included.

(3)

You will pay a maximum sales charge of 2.75% of the Public Offering Price per Unit (equivalent to 2.75%\nof the net amount invested) which consists of an initial sales charge, a deferred sales charge and a creation and development fee. The\nsales charges are described in the “Fee Table.”

(4)

Each listed Security is valued at its last closing sale price at the Evaluation Time on the business day\nprior to the Initial Date of Deposit. If a Security is not listed, or if no closing sale price exists, it is valued at its closing ask\nprice on such date. See “Public Offering—The Value of the Securities.” Evaluations for purposes of determining the purchase,\nsale or redemption price of Units are made as of the close of trading on the New York Stock Exchange (“NYSE”) (generally 4:00\np.m. Eastern time) on each day on which it is open (the “Evaluation Time”).

(5)

The creation and development fee will be deducted from the assets of the Trust at the end of the initial\noffering period and the estimated organization costs per Unit will be deducted from the assets of the Trust at the earlier of six months\nafter the Initial Date of Deposit or the end of the initial offering period. If Units are redeemed prior to any such reduction, these\nfees will not be deducted from the redemption proceeds. See “Redeeming Your Units.”

(6)

See “Amending or Terminating the Indenture.”

(7)

The Trustee will distribute money from the Income Account, as determined at the semi-annual Income Account\nDistribution Record Date, semi-annually on the twenty-fifth day of each June and December to Unit holders of record on the tenth day of\nsuch months provided the amount in the Income Account equals at least $1.00 per 100 Units. The Trustee will make distributions from the\nCapital Account monthly on the twenty-fifth day of each month to Unit holders of record on the tenth day of such month provided the amount\navailable for distribution from the Capital Account equals at least $1.00 per 100 Units. See “Income and Capital Distributions.”

\n \n \n

Fee Table (Unaudited)

Fee Table

This\nFee Table describes the fees and expenses that you may, directly or indirectly, pay if you buy and hold Units of the Trust. See “Public\nOffering” and “Expenses and Charges.” Although the Trust has a term of approximately two years and is a unit investment\ntrust rather than a mutual fund, this information allows you to compare fees.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

		Amount per Unit
Unit Holder Sales Fees (as a percentage of public offering price)
Maximum Sales Charge
Initial sales charge\t	0.00%	(a)	$	.000
Deferred sales charge\t	2.25%	(b)	$	.225
Creation and development fee\t	0.50%	(c)	$	.050
Maximum sales charge (including creation and development fee)\t	2.75%		$	.275
Organization Costs (as a percentage of public offering price)
Estimated organization costs\t	.510%	(d)	$	.0510
Estimated Annual Trust Operating Expenses^(e)
(as a percentage of average net assets)
Portfolio supervision, bookkeeping, administrative and evaluation fees\t	.080%		$	.0080
Trustee’s fee and other operating expenses\t\t\t	.138%	(f)	$	.0138
Total\t\t\t	.218%		$	.0218

Example

This\nexample is intended to help you compare the cost of investing in the Trust with the cost of investing in other investment products. The\nexample assumes that you invest $10,000 in the Trust for the periods shown. The example also assumes a 5% return on your investment each\nyear and that the Trust’s operating expenses stay the same. The example does not take into consideration transaction fees which\nmay be charged by certain broker/dealers for processing redemption requests. Although your actual costs may vary, based on these assumptions\nyour costs, assuming you sell or redeem your Units at the end of each period, would be:

\n \n \n \n \n \n \n

1 Year	2 Years
$348	$370

The\nexample will not differ if you hold rather than sell your Units at the end of each period.

(a)

The combination of the initial and deferred sales charge comprises what\nwe refer to as the “transactional sales charge.” The initial sales charge is actually equal to the difference between the\nmaximum sales charge of 2.75% and the sum of any remaining deferred sales charge and creation and development fee. When the Public Offering\nPrice per Unit equals $10, there is no initial sales charge. If the price you pay for your Units exceeds $10 per Unit, you will pay an\ninitial sales charge.

(b)

The deferred sales charge is a fixed dollar amount equal to $.225 per Unit\nwhich, as a percentage of the Public Offering Price, will vary over time. The deferred sales charge will be deducted in three monthly\ninstallments commencing February 19, 2027.

(c)

The creation and development fee compensates the Sponsor for creating and\ndeveloping the Trust. The creation and development fee is a charge of $.050 per Unit collected at the end of the initial offering period,\nwhich is expected to be approximately three months from the Initial Date of Deposit. If the price you pay for your Units exceeds $10 per\nUnit, the creation and development fee will be less than 0.50%; if the price you pay for your Units is less than $10 per Unit, the creation\nand development fee will exceed 0.50%. If you purchase Units after the initial offering period, you will not be assessed the creation\nand development fee.

(d)

Estimated organization costs will be deducted from the assets of the Trust\nat the earlier of six months after the Initial Date of Deposit or the end of the initial offering period. Estimated organization costs\nare assessed on a fixed dollar amount per Unit basis which, as a percentage of average net assets, will vary over time.

(e)

Each of the fees listed herein is assessed on a fixed dollar amount per\nUnit basis which, as a percentage of average net assets, will vary over time.

(f)

Other operating expenses for the Trust do not include brokerage costs and\nother portfolio transaction fees for the Trust. In certain circumstances the Trust may incur additional expenses not set forth above.\nSee “Expenses and Charges.”

\n \n \n

Report of Independent
\n Registered Public Accounting Firm

Report of Independent Registered Public Accounting\n Firm

To the Unit Holders and the Sponsor,\nFirst Trust Portfolios L.P., of FT 13299

Opinion on the Statement of Net\nAssets

We\nhave audited the accompanying statement of net assets, including the schedule of investments, of FT 13299, comprising Biotechnology\nPortfolio, Series 71 (the “Trust”), one of the series constituting the FT Series, as of the opening of business on October\n30, 2026 (Initial Date of Deposit), and the related notes. In our opinion, the statement of net assets presents fairly, in all material\nrespects, the financial position of the Trust as of the opening of business on October 30, 2026 (Initial Date of Deposit), in conformity\nwith accounting principles generally accepted in the United States of America.

Basis for Opinion

This\nstatement of net assets is the responsibility of the Trust’s Sponsor. Our responsibility is to express an opinion on this statement\nof net assets based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United\nStates) (PCAOB) and are required to be independent with respect to the Trust in accordance with the U.S. federal securities laws and the\napplicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We\nconducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain\nreasonable assurance about whether the statement of net assets is free of material misstatement, whether due to error or fraud. The Trust\nis not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit\nwe are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion\non the effectiveness of the Trust’s internal control over financial reporting. Accordingly, we express no such opinion.

Our\naudit included performing procedures to assess the risks of material misstatement of the statement of net assets, whether due to error\nor fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding\nthe amounts and disclosures in the statement of net assets. Our audit also included evaluating the accounting principles used and significant\nestimates made by the Trust’s Sponsor, as well as evaluating the overall presentation of the statement of net assets. Our procedures\nincluded confirmation of the irrevocable letter of credit held by The Bank of New York Mellon, the Trustee, and deposited in the Trust\nfor the purchase of securities, as shown in the statement of net assets, as of the opening of business on October 30, 2026, by correspondence\nwith the Trustee. We believe that our audit provides a reasonable basis for our opinion.

/s/ DELOITTE & TOUCHE LLP

Chicago, Illinois
\nOctober 30, 2026

We have\nserved as the auditor of one or more investment companies sponsored by First Trust Portfolios L.P. since 2001.

\n \n \n

Statement of Net Assets

Biotechnology\nPortfolio, Series 71
\nFT 13299

At the Opening of Business on the Initial\nDate of Deposit—October 30, 2026

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

NET ASSETS
Investment in Securities represented by purchase contracts (1) (2)\t	$	160,840
Less liability for reimbursement to Sponsor for organization costs (3)\t		(820	)
Less liability for deferred sales charge (4)\t		(3,619	)
Less liability for creation and development fee (5)\t		(804	)
Net assets\t	$	155,597
Units outstanding\t		16,084
Net asset value per Unit (6)\t	$	9.674
ANALYSIS OF NET ASSETS
Cost to investors (7)\t	$	160,840
Less maximum sales charge (7)\t		(4,423	)
Less estimated reimbursement to Sponsor for organization costs (3)\t		(820	)
Net assets\t	$	155,597

NOTES TO STATEMENT\nOF NET ASSETS

The Trust is registered as a unit investment\ntrust under the Investment Company Act of 1940. The Sponsor is responsible for the preparation of financial statements in accordance with\naccounting principles generally accepted in the United States which require the Sponsor to make estimates and assumptions that affect\namounts reported herein. Actual results could differ from those estimates. The Trust intends to comply in its initial fiscal year and\nthereafter with provisions of the Internal Revenue Code applicable to regulated investment companies and as such, will not be subject\nto federal income taxes on otherwise taxable income (including net realized capital gains) distributed to Unit holders.

(1)

The Trust invests in a diversified portfolio of common stocks. Aggregate\ncost of the Securities listed under “Schedule of Investments” is based on their aggregate underlying value. The Trust has\na Mandatory Termination Date of October 30, 2028.

(2)

An irrevocable letter of credit issued by The Bank of New York Mellon,\nof which approximately $300,000 has been allocated to the Trust, has been deposited with the Trustee as collateral, covering the monies\nnecessary for the purchase of the Securities according to their purchase contracts.

(3)

A portion of the Public Offering Price consists of an amount sufficient\nto reimburse the Sponsor for all or a portion of the costs of establishing the Trust. These costs have been estimated at $.0510 per Unit.\nA payment will be made at the earlier of six months after the Initial Date of Deposit or the end of the initial offering period to an\naccount maintained by the Trustee from which the obligation of the investors to the Sponsor will be satisfied. To the extent that actual\norganization costs of the Trust are greater than the estimated amount, only the estimated organization costs added to the Public Offering\nPrice will be reimbursed to the Sponsor and deducted from the assets of the Trust.

(4)

Represents the amount of mandatory deferred sales charge distributions\nof $.225 per Unit, payable to the Sponsor in three equal monthly installments beginning on February 19, 2027 and on the twentieth day\nof each month thereafter (or if such date is not a business day, on the preceding business day) through April 20, 2027. If Unit holders\nredeem Units before April 20, 2027, they will have to pay the remaining amount of the deferred sales charge applicable to such Units when\nthey redeem them.

(5)

The creation and development fee ($.050 per Unit) is payable by the Trust\non behalf of Unit holders out of assets of the Trust at the end of the initial offering period. If Units are redeemed prior to the close\nof the initial offering period, the fee will not be deducted from the proceeds.

(6)

Net asset value per Unit is calculated by dividing the Trust’s net\nassets by the number of Units outstanding. This figure includes organization costs and the creation and development fee, which will only\nbe assessed to Units outstanding at the earlier of six months after the Initial Date of Deposit or the end of the initial offering period\nin the case of organization costs or the close of the initial offering period in the case of the creation and development fee.

(7)

The aggregate cost to investors in the Trust includes a maximum sales charge\n(comprised of an initial and a deferred sales charge and the creation and development fee) computed at the rate of 2.75% of the Public\nOffering Price (equivalent to 2.75% of the net amount invested, exclusive of the deferred sales charge and the creation and development\nfee), assuming no reduction of the maximum sales charge as set forth under “Public Offering.”

\n \n \n

Schedule of Investments

Biotechnology\nPortfolio, Series 71
\nFT 13299

At the Opening of Business on the Initial\nDate of Deposit—October 30, 2026

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

		Percentage
		of Aggregate		Number	Market		Cost of
Ticker Symbol and	Offering	of		Value per	Securities to
Name of Issuer of Securities (1)(3)	Price	Shares		Share	the Trust (2)
Common Stocks (100%):
Health Care (100%):
ABBV	AbbVie Inc.\t		4%			22		$	290.79	$	6,397
AMGN	Amgen Inc.\t		4%			14			460.73		6,450
ARGX	argenx SE (ADR) †*\t		4%			7			897.85		6,285
ASND	Ascendis Pharma A/S †*\t		4%			25			253.00		6,325
ONC	BeOne Medicines Ltd. (ADR) †*\t		4%			17			371.56		6,317
BIIB	Biogen Inc. *\t		4%			26			249.65		6,491
BMRN	BioMarin Pharmaceutical Inc. *\t		4%			112			57.49		6,439
BBIO	BridgeBio Pharma, Inc. *\t		4%			91			70.73		6,436
EXEL	Exelixis, Inc. *\t		4%			97			66.20		6,421
GMAB	Genmab A/S (ADR) †*\t		4%			114			56.49		6,440
GILD	Gilead Sciences, Inc.\t		4%			39			165.61		6,459
HALO	Halozyme Therapeutics, Inc. *\t		4%			49			131.18		6,428
INCY	Incyte Corporation *\t		4%			55			116.80		6,424
KNSA	Kiniksa Pharmaceuticals International, Plc (Class A) †*\t		4%			66			97.56		6,439
KRYS	Krystal Biotech, Inc. *\t		4%			20			324.55		6,491
MDGL	Madrigal Pharmaceuticals, Inc. *\t		4%			15			431.70		6,475
MIRM	Mirum Pharmaceuticals, Inc. *\t		4%			74			86.39		6,393
NBIX	Neurocrine Biosciences, Inc. *\t		4%			44			146.38		6,441
REGN	Regeneron Pharmaceuticals, Inc.\t		4%			8			818.77		6,550
RVMD	Revolution Medicines, Inc. *\t		4%			34			190.27		6,469
TGTX	TG Therapeutics, Inc. *\t		4%			111			58.08		6,447
TMO	Thermo Fisher Scientific Inc.\t		4%			9			709.18		6,383
UTHR	United Therapeutics Corporation *\t		4%			11			593.54		6,529
VRTX	Vertex Pharmaceuticals Incorporated *\t		4%			12			540.00		6,480
ZYME	Zymeworks Inc. *\t		4%			224			28.71		6,431
	Total Investments\t\t		100%							$	160,840

See\n“Notes to Schedule of Investments” on page 8.

NOTES TO SCHEDULE OF INVESTMENTS

(1)

All Securities are represented by regular way contracts to purchase such\nSecurities which are backed by an irrevocable letter of credit deposited with the Trustee. The Sponsor entered into purchase contracts\nfor the Securities on October 30, 2026. Such purchase contracts are expected to settle within one business day.

(2)

The cost of the Securities to the Trust represents the aggregate underlying\nvalue with respect to the Securities acquired (generally determined by the closing sale prices of the listed Securities and the ask prices\nof over-the-counter traded Securities at the Evaluation Time on the business day prior to the Initial Date of Deposit). The cost of Securities\nto the Trust may not compute due to rounding the market value per share. The valuation of the Securities has been determined by the Sponsor.\nIn accordance with Financial Accounting Standards Board Accounting Standards Codification 820, “Fair Value Measurement,” the\nTrust’s investments are classified as Level 1, which refers to securities traded in an active market. The cost of the Securities\nto the Sponsor and the Sponsor’s loss (which is the difference between the cost of the Securities to the Sponsor and the\ncost of the Securities to the Trust) are $162,712 and $1,872, respectively.

(3)

Common stocks of companies headquartered or incorporated outside the United\nStates comprise approximately 20% of the investments of the Trust (consisting of Belgium, 4%; Denmark, 8%; Switzerland, 4% and United\nKingdom, 4%).

†

This Security represents the common stock of a foreign company which trades\ndirectly or through an American Depositary Receipt/ADR on the over-the-counter market or on a U.S. national securities exchange.

This Security represents a non-income producing security.

\n \n \n

The FT Series

The FT Series Defined.

We,\nFirst Trust Portfolios L.P. (the “Sponsor”), have created hundreds of similar yet separate series of a unit investment trust\nwhich we have named the FT Series. The series to which this prospectus relates, FT 13299, consists of a single portfolio known as\nBiotechnology Portfolio, Series 71.

The\nTrust was created under the laws of the State of New York by a Trust Agreement (the “Indenture”) dated the Initial Date of\nDeposit. This agreement, entered into among First Trust Portfolios L.P., as Sponsor, The Bank of New York Mellon as Trustee and First\nTrust Advisors L.P. as Portfolio Supervisor, governs the operation of the Trust.

You may get more specific details concerning the nature, structure\nand risks of this product in an “Information Supplement” by calling the Sponsor at 800–621–1675, dept. code 2.

How We Created the Trust.

On\nthe Initial Date of Deposit, we deposited a portfolio of common stocks with the Trustee and, in turn, the Trustee delivered documents\nto us representing our ownership of the Trust in the form of units (“Units”).

After\nthe Initial Date of Deposit, we may deposit additional Securities in the Trust, or cash (including a letter of credit or the equivalent)\nwith instructions to buy more Securities, to create new Units for sale. If we create additional Units, we will attempt, to the extent\npracticable, to maintain the percentage relationship established among the Securities on the Initial Date of Deposit (as set forth in\n“Schedule of Investments”), adjusted to reflect the sale, redemption or liquidation of any of the Securities or any stock\nsplit or a merger or other similar event affecting the issuer of the Securities.

Since\nthe prices of the Securities will fluctuate daily, the ratio of Securities in the Trust, on a market value basis, will also change daily.\nThe portion of Securities represented by each Unit will not change as a result of the deposit of additional Securities or cash in the\nTrust. If we deposit cash, you and new investors may experience a dilution of your investment. This is because prices of Securities will\nfluctuate between the time of the cash deposit and the purchase of the Securities, and because the Trust pays the associated brokerage\nfees. To reduce this dilution, the Trust will try to buy the Securities as close to the Evaluation Time and as close to the evaluation\nprice as possible. In addition, because the Trust pays the brokerage fees associated with the creation of new Units and with the sale\nof Securities to meet redemption and exchange requests, frequent redemption and exchange activity will likely result in higher brokerage\nexpenses.

An\naffiliate of the Trustee may receive these brokerage fees or the Trustee may retain and pay us (or our affiliate) to act as agent for\nthe Trust to buy Securities. If we or an affiliate of ours act as agent to the Trust, we will be subject to the restrictions under the\nInvestment Company Act of 1940, as amended (the “1940 Act”). When acting in an agency capacity, we may select various broker/dealers\nto execute securities transactions on behalf of the Trust, which may include broker/dealers who sell Units of the Trust. We do not consider\nsales of Units of the Trust or any other products sponsored by First Trust as a factor in selecting such broker/dealers.

We\ncannot guarantee that the Trust will keep its present size and composition for any length of time. Securities may be periodically sold\nunder certain circumstances to satisfy Trust obligations, to meet redemption requests and, as described in “Removing Securities\nfrom the Trust,” to maintain the sound investment character of the Trust, and the proceeds received by the Trust will be used to\nmeet Trust obligations or distributed to Unit holders. However, Securities will not be sold to take advantage of market fluctuations or\nchanges in anticipated rates of appreciation or depreciation, or if they no longer meet the criteria by which they were selected. You\nwill not be able to dispose of or vote any of the Securities in the Trust. As the holder of the Securities, the Trustee will vote the\nSecurities and, except as described in “Removing Securities from the Trust,” will endeavor to vote the Securities such that\nthe Securities are voted as closely as possible in the same manner and the same general proportion as are the Securities held by owners\nother than such Trust.

Neither\nwe nor the Trustee will be liable for a failure in any of the Securities. However, if a contract for the purchase of any of the Securities\ninitially deposited in the Trust fails, unless we can purchase substitute Securities (“Replacement Securities”) we will refund\nto you that portion of the purchase price and transactional sales charge resulting from the failed contract on the next Income Account\nDistribution Date. Any Replacement Security the Trust acquires will be identical to those from the failed contract.

\n \n \n

Portfolio

Objective.

The\nTrust consists of a portfolio of common stocks. The Trust seeks above-average capital appreciation. Under normal circumstances, the Trust\ninvests at least 80% of its assets in biotechnology companies. Biotechnology companies are companies classified under the Biotechnology\nor Life Sciences Tools & Services industries of the Global Industry Classification Standard (GICS). The Trust is concentrated (i.e.,\ninvests 25% or more of Trust assets) in common stocks of companies within the health care sector.

Portfolio Selection Process.

Our\nselection process attempts to find the common stocks with the best prospects for above-average capital appreciation by identifying those\nthat meet our investment objective, trade at attractive valuations, and, in our opinion, are likely to exceed market expectations of future\ncash flows.

While not a part of the Trust’s portfolio\nselection process, the Trust also invests in dividend-paying securities, foreign securities, depositary receipts and companies with various\nmarket capitalizations.

As\nwith any similar investments, there can be no assurance that the objective of the Trust will be achieved. See “Risk Factors”\nfor a discussion of the risks of investing in the Trust.

\n \n \n

Risk Factors

Price Volatility. The Trust invests\nin common stocks. The value of the Trust’s Units will fluctuate with changes in the value of these common stocks. Common stock prices\nfluctuate for several reasons including changes in investors’ perceptions of the financial condition of an issuer or the general\ncondition of the relevant stock market, such as market volatility, or when political or economic events affecting the issuers occur. In\naddition, common stock prices may be particularly sensitive to rising interest rates, as the cost of capital rises and borrowing costs\nincrease, negatively impacting issuers.

Because the Trust is not managed, the Trustee\nwill not sell stocks in response to or in anticipation of market fluctuations, as is common in managed investments. As with any investment,\nwe cannot guarantee that the performance of the Trust will be positive over any period of time, or that you won’t lose money. Units\nof the Trust are not deposits of any bank and are not insured or guaranteed by the Federal Deposit Insurance Corporation or any other\ngovernment agency.

Market Risk. Market risk is the risk that\na particular security, or Units of the Trust in general, may fall in value or underperform other investments. Securities are subject to\nmarket fluctuations caused by such factors as economic, political, regulatory or market developments, changes in interest rates and perceived\ntrends in securities prices. As a means to fight inflation, the Federal Reserve and certain foreign central banks have raised interest\nrates and may continue to do so. Potential future bank failures could result in disruption to the broader banking industry or markets\ngenerally and reduce confidence in financial institutions and the economy as a whole, which may also heighten market volatility and reduce\nliquidity. Additionally, challenges in commercial real estate markets, including declining valuations and elevated vacancies, could have\na broader impact on financial markets. In addition, local, regional or global events such as war, acts of terrorism, natural disasters,\nspread of infectious diseases or other public health issues, recessions, political turbulence or other events could have a significant\nnegative impact on the Trust and its investments. The ongoing adversarial political climate in the United States, as well as political\nand diplomatic events both domestic and abroad, have had and may continue to have an adverse impact on the U.S. regulatory landscape,\nmarkets and investor behavior, which could have a negative impact on the Trust’s investments and operations. The upcoming elections\nin the United States may result in significant impacts to international trade relations, tax and immigration policies, and other aspects\nof the national and international political and financial landscape, which could affect, among other things, inflation and the securities\nmarkets generally. Administrative actions against companies in certain industries, such as the defense industry, prohibiting them from\npaying dividends or engaging in stock buybacks, may negatively impact the performance of such companies and the Trust’s investments.\nOngoing armed conflicts between Russia and Ukraine in Europe and among the United States, Israel, Iran, Hamas, Hezbollah and other militant\ngroups in the Middle East, have caused and could continue to cause significant market disruptions and volatility within the markets in\nRussia, Europe, the Middle East, the United States, and other nations. Such events may also disrupt global trade and supply chains, increase\nsanctions and other governmental actions, and contribute to volatility in oil and natural gas markets. The hostilities and sanctions resulting\nfrom those hostilities could have a significant impact on certain Trust investments as well as Trust performance. The economies of the\nUnited States and its trading partners, as well as the financial markets generally, may be adversely impacted by trade disputes, including\nthe imposition of tariffs, and other matters. A public health crisis, and the ensuing policies enacted by governments and central banks\nin response, could cause significant volatility and uncertainty in global financial markets, negatively impacting global growth prospects.\nSuch events may affect certain geographic regions, countries, sectors and industries more significantly than others. Advancements in technology\nmay also adversely impact markets and the overall performance of the Trust. For instance, the economy may be significantly impacted by\nthe advanced development and increased regulation of artificial intelligence. Additionally, cybersecurity breaches of both government\nand non-government entities could have negative impacts on infrastructure and the ability of such entities, including the Trust, to operate\nproperly. Such events could adversely affect the prices and liquidity of the Trust’s portfolio securities and could result in disruptions\nin the trading markets. Any such circumstances could have a materially negative impact on the value of the Trust’s Units and result\nin increased market volatility.

Dividends. Common stocks may pay\ndividends, but there is no guarantee that the issuers of the common stocks will declare dividends in the future or that, if declared,\nthey will either remain at current levels or increase over time.

Concentration\nRisk. When 25% or more of a trust’s portfolio is invested in securities issued by companies within a single sector, the trust\nis considered to be concentrated in that particular sector. A portfolio concentrated in one or more sectors may present more risks than\na portfolio broadly diversified over several sectors.

The\nTrust is concentrated in common stocks of companies within the health care sector.

Health\nCare. General risks of health care companies include extensive competition, generic drug sales resulting from the loss of patent protection,\nproduct liability litigation and evolving government regulation. Research and development costs of bringing new drugs to market are substantial,\nand there is no guarantee that a product will ever come to market. Health care facility operators may be affected by the demand for services,\nthe ability of the facility to provide the services required, efforts by government or insurers to limit rates, restriction of government\nfinancial assistance and competition from other providers. The health care sector may be impacted if Congress proposes legislation regarding\nreform on the health care sector, changes in current laws regarding access to health insurance and the overall risks and costs of compliance\nwith such regulations. Whether these proposals will be adopted and their possible long-term effects on the health care industry remains\nuncertain and cannot be predicted. In addition, health crises, such as a pandemic outbreak, can severely impact the health care industry\nin particular. These crises can disrupt health care services and processes, strain resources and supplies, and are often increasingly\ndifficult to assess and impossible to predict.

Biotechnology/Pharmaceutical.\nThe Trust invests in biotechnology and pharmaceutical companies which include companies involved in the health care sector. Biotechnology\nand pharmaceutical companies are subject to changing government regulation which could have a negative effect on the price, profitability\nand availability of their products and services. Legislative proposals concerning health care are proposed in Congress from time to time.\nThese proposals span a wide range of topics, including cost and price controls (which might include a freeze on the prices of prescription\ndrugs). Whether these proposals will be adopted and their possible effects on the pharmaceutical and biotechnology industries remain uncertain\nand cannot be predicted. In addition, such companies face increasing competition from existing generic drugs, the termination of their\npatent protection for certain drugs and technological advances which render their products or services obsolete. The research and development\ncosts required to bring a drug to market are substantial and may include a lengthy review by the government, with no guarantee that the\nproduct will ever be brought to market or show a profit. In addition, the potential for an increased amount of required disclosure of\nproprietary scientific information could negatively impact the competitive position of these companies. Many of these companies may not\noffer certain drugs or products for several years, and as a result, may have significant losses of revenue and earnings.

Foreign\nSecurities. Risks of foreign securities include higher brokerage costs; different accounting standards; expropriation, nationalization\nor other adverse political or economic developments; currency devaluations, blockages or transfer restrictions; restrictions on foreign\ninvestments and exchange of securities; inadequate financial information; lack of liquidity of certain foreign markets; and less government\nsupervision and regulation of exchanges, brokers, and issuers in foreign countries. Certain foreign markets have experienced heightened\nvolatility due to recent negative political or economic developments or natural disasters. Securities issued by non-U.S. issuers may pay\ndividends in foreign currencies and may be principally traded in foreign currencies. Therefore, there is a risk that the U.S. dollar value\nof these dividend payments and/or securities will vary with fluctuations in foreign exchange rates.

Depositary\nReceipts Risk. Depositary receipts (which may include American Depositary Receipts/ADRs, Global Depositary Receipts/GDRs, New York\nRegistry Shares, and/or similarly structured securities) are securities issued by a bank or trust company reflecting ownership of underlying\nsecurities issued by a foreign company. Depositary receipts may be less liquid than the underlying shares in their primary trading market.\nAny distributions paid to the holders of depositary receipts are usually subject to a fee charged by the depositary. Holders of depositary\nreceipts may have limited voting rights, and investment restrictions in certain countries may adversely impact the value of depositary\nreceipts because such restrictions may limit the ability to convert shares into depositary receipts and vice versa. Such restrictions\nmay cause shares of the underlying issuer to trade at a discount or premium to the market price of the depositary receipts. Moreover,\ndepositary receipts may be “sponsored” or “unsponsored.” Sponsored depositary receipts are established jointly\nby a depositary and the underlying issuer, whereas unsponsored depositary receipts may be established by a depositary without participation\nby the underlying issuer. Holders of unsponsored depositary receipts generally bear all the costs associated with establishing the unsponsored\ndepositary receipts. In addition, the issuers of the securities underlying unsponsored depositary receipts are not obligated to disclose\nmaterial information in the U.S. and, therefore, there may be less information available regarding such issuers and there may not be a\ncorrelation between such information and the market value of the depositary receipts.

Small\nand/or Mid Capitalization Companies. Investing in stocks of small and/or mid capitalization companies may involve greater risk than\ninvesting in larger companies. For example, such companies may have limited product lines, as well as shorter operating histories, less\nexperienced management and more limited financial resources than larger companies. Securities of such companies generally trade in lower\nvolumes and are generally subject to greater and less predictable changes in price than securities of larger companies. In addition,\nsmall and mid-cap stocks may not be widely followed by the investment community, which may result in low demand.

Large\nCapitalization Companies. The return on investment in stocks of large capitalization companies may be less than the return on investment\nin stocks of small and/or mid capitalization companies. Large capitalization companies may also grow at a slower rate than the overall\nmarket.

Cybersecurity Risk. As the use of Internet\ntechnology has become more prevalent in the course of business, the Trust has become more susceptible to potential operational, information\nsecurity and related risks through breaches in cybersecurity. A breach in cybersecurity refers to both intentional and unintentional events\nthat may cause the Trust to lose proprietary information, suffer data corruption or lose operational capacity, any of which could result\nin a material adverse effect on the Trust or its Unit holders. Such events could cause the Sponsor of the Trust to incur regulatory penalties,\nreputational damage, additional compliance costs associated with corrective measures and/or financial loss. Cybersecurity breaches may\ninvolve unauthorized access to digital information systems utilized by the Trust through “hacking” or malicious software coding,\nbut may also result from outside attacks such as denial-of service attacks through efforts to make network services unavailable to intended\nusers. Emerging threats like ransomware or zero-day exploits could also cause disruptions to Trust operations. In addition, cybersecurity\nbreaches of the Trust’s third-party service providers, or issuers in which the Trust invests, can also subject the Trust to many\nof the same risks associated with direct cybersecurity breaches. Further, errors, misconduct, or compromise of accounts of employees of\nthe Sponsor, Portfolio Supervisor or the Trust’s third-party service providers can also create material cybersecurity risks. The\nSponsor of, and third-party service provider to, the Trust have established risk management systems designed to reduce the risks associated\nwith cybersecurity. However, there is no guarantee that such efforts will succeed, especially because the Trust does not directly control\nthe cybersecurity systems of issuers or third-party service providers. Cybersecurity incidents may also trigger Trust obligations under\ndata privacy laws, potentially increasing notification and compliance burdens. Cybersecurity incidents affecting issuers in whose securities\nthe Trust invests may also have a negative impact on the value of the securities of such issuers, and in turn, the value of the Trust.

Operational Risk. The Trust is subject\nto risks arising from various operational factors, including, but not limited to, human error, processing and communication errors, errors\nof the Trust’s service providers, counterparties or other third-parties, failed or inadequate processes and technology or systems\nfailures. These errors or failures may adversely affect the Trust’s operations, including its ability to execute its investment\nprocess, calculate or disseminate its NAV in a timely manner, and process purchases or redemptions. The Trust relies on third-parties\nfor a range of services. Any delay or failure relating to engaging or maintaining such service providers may affect the Trust’s\nability to meet its investment objective. Although the Trust seeks to reduce these operational risks through controls and procedures,\nthere is no way to completely protect against such risks.

Legislation/Litigation.\nFrom time to time, various legislative initiatives are proposed in the United States and abroad which may have a negative impact on certain\nof the companies represented in the Trust. In addition, litigation regarding any of the issuers of the Securities, or the industries represented\nby these issuers, may negatively impact the value of these Securities. We cannot predict what impact any pending or proposed legislation\nor pending or threatened litigation will have on the value of the Securities.

\n \n \n

Public Offering

The Public Offering Price.

Units\nwill be purchased at the Public Offering Price, the price per Unit of which is comprised of the following:

•

The aggregate underlying value of the Securities;

•

The amount of any cash in the Income and Capital Accounts;

•

Dividends receivable on Securities; and

•

The maximum sales charge (which combines an initial upfront sales charge, a deferred sales charge\nand the creation and development fee).

The\nprice you pay for your Units will differ from the amount stated under “Summary of Essential Information” due to various factors,\nincluding fluctuations in the prices of the Securities and changes in the value of the Income and/or Capital Accounts.

Although\nyou are not required to pay for your Units until one business day following your order (the “date of settlement”), you may\npay before then. You will become the owner of Units (“Record Owner”) on the date of settlement if payment has been received.\nIf you pay for your Units before the date of settlement, we may use your payment during this time and it may be considered a benefit to\nus, subject to the limitations of the Securities Exchange Act of 1934, as amended.

Organization Costs. Securities purchased\nwith the portion of the Public Offering Price intended to be used to reimburse the Sponsor for the Trust’s organization costs (including\ncosts of preparing the registration statement, the Indenture and other closing documents, registering Units with the SEC and states, the\ninitial audit of the Trust’s statement of net assets, legal fees and the initial fees and expenses of the Trustee) will be purchased\nin the same proportionate relationship as all the Securities contained in the Trust. Securities will be sold to reimburse the Sponsor\nfor the Trust’s organization costs at the earlier of six months after the Initial Date of Deposit or the end of the initial offering\nperiod (a significantly shorter time period than the life of the Trust). During the period ending with the earlier of six months after\nthe Initial Date of Deposit or the end of the initial offering period, there may be a decrease in the value of the Securities. To the\nextent the proceeds from the sale of these Securities are insufficient to repay the Sponsor for Trust organization costs, the Trustee\nwill sell additional Securities to allow the Trust to fully reimburse the Sponsor. In that event, the net asset value per Unit of the\nTrust will be reduced by the amount of additional Securities sold. Although the dollar amount of the reimbursement due to the Sponsor\nwill remain fixed and will never exceed the per Unit amount set forth for the Trust in “Notes to Statement of Net Assets,”\nthis will result in a greater effective cost per Unit to Unit holders for the reimbursement to the Sponsor. To the extent actual organization\ncosts are less than the estimated amount, only the actual organization costs will ultimately be charged to the Trust. When Securities\nare sold to reimburse the Sponsor for organization costs, the Trustee will sell Securities, to the extent practicable, which will maintain\nthe same proportionate relationship among the Securities contained in the Trust as existed prior to such sale.

Minimum Purchase.

The minimum amount per account you can\npurchase of the Trust is generally $1,000 worth of Units ($500 if you are purchasing Units for your Individual Retirement Account or any\nother qualified retirement plan), but such amounts may vary depending on your selling firm.

Maximum Sales Charge.

The maximum sales charge of 2.75% per Unit\nis comprised of a transactional sales charge and a creation and development fee. After the initial offering period the maximum sales charge\nwill be reduced by 0.50%, to reflect the amount of the previously charged creation and development fee.

Transactional Sales Charge.

The transactional sales charge you will\npay has both an initial and a deferred component.

Initial Sales Charge. The initial\nsales charge, which you will pay at the time of purchase, is equal to the difference between the maximum sales charge of 2.75% of the\nPublic Offering Price and the sum of the maximum remaining deferred sales charge and creation and development fee (initially $.275 per\nUnit). On the Initial Date of Deposit, and any other day the Public Offering Price per Unit equals $10.00, there is no initial sales charge.\nThereafter, you will pay an initial sales charge when the Public Offering Price per Unit exceeds $10.00 and as deferred sales charge and\ncreation and development fee payments are made.

Monthly Deferred Sales Charge. In\naddition, three monthly deferred sales charges of $.075 per Unit will be deducted from the Trust’s assets on approximately the twentieth\nday of each month from February 19, 2027 through April 20, 2027. If you buy Units at a price of less than $10.00 per Unit, the dollar\namount of the deferred sales charge will not change, but the deferred sales charge on a percentage basis will be more than 2.25% of the\nPublic Offering Price.

If you purchase Units after the last deferred\nsales charge payment has been assessed, your transactional sales charge will consist of a one-time initial sales charge of 2.25% of the\nPublic Offering Price (equivalent to 2.302% of the net amount invested).

Creation and Development Fee.

As Sponsor, we will also receive, and the\nUnit holders will pay, a creation and development fee. See “Expenses and Charges” for a description of the services provided\nfor this fee. The creation and development fee is a charge of $.050 per Unit collected at the end of the initial offering period. If you\nbuy Units at a price of less than $10.00 per Unit, the dollar amount of the creation and development fee will not change, but the creation\nand development fee on a percentage basis will be more than 0.50% of the Public Offering Price.

Discounts for Certain Persons.

The maximum sales charge is 2.75% per Unit\nand the maximum dealer concession is 2.00% per Unit.

If you are purchasing Units for an investment\naccount, the terms of which provide that your registered investment advisor or registered broker/dealer (a) charges periodic fees\nin lieu of commissions; (b) charges for financial planning, investment advisory or asset management services; or (c) charges\na comprehensive “wrap fee” or similar fee for these or comparable services (“Fee Accounts”), you will not be assessed\nthe transactional sales charge described above on such purchases. These Units will be designated as Fee Account Units and, depending upon\nthe purchase instructions we receive, assigned either a Fee Account Cash CUSIP Number, if you elect to have distributions paid to you,\nor a Fee Account Reinvestment CUSIP Number, if you elect to have distributions reinvested into additional Units of the Trust. Certain\nFee Account Unit holders may be assessed transaction or other account fees on the purchase and/or redemption of such Units by their registered\ninvestment advisor, broker/dealer or other processing organizations for providing certain transaction or account activities. Fee Account\nUnits are not available for purchase in the secondary market. We reserve the right to limit or deny purchases of Units not subject to\nthe transactional sales charge by investors whose frequent trading activity we determine to be detrimental to the Trust.

Employees, officers and directors (and\nimmediate family members) of the Sponsor, our related companies, and dealers and their affiliates will purchase Units at the Public Offering\nPrice less the applicable dealer concession, subject to the policies of the related selling firm. Immediate family members include spouses,\nor the equivalent if recognized under local law, children or step-children under the age of 21 living in the same household, parents or\nstep-parents and trustees, custodians or fiduciaries for the benefit of such persons. Only employees, officers and directors of companies\nthat allow their employees to participate in this employee discount program are eligible for the discounts.

You will be charged the deferred sales\ncharge per Unit regardless of the price you pay for your Units or whether you are eligible to receive any discounts. However, if the purchase\nprice of your Units was less than $10.00 per Unit or if you are eligible to receive a discount such that the maximum sales charge you\nmust pay is less than the applicable maximum deferred sales charge, including Fee Account Units, you will be credited additional Units\nwith a dollar value equal to the difference between your maximum sales charge and the maximum deferred sales charge at the time you buy\nyour Units. If you elect to have distributions reinvested into additional Units of the Trust, in addition to the reinvestment Units you\nreceive you will also be credited additional Units with a dollar value at the time of reinvestment sufficient to cover the amount of any\nremaining deferred sales charge and creation and development fee to be collected on such reinvestment Units. The dollar value of these\nadditional credited Units (as with all Units) will fluctuate over time, and may be less on the dates deferred sales charges or the creation\nand development fee are collected than their value at the time they were issued.

The Value of the Securities.

The Sponsor will determine the aggregate\nunderlying value of the Securities in the Trust as of the Evaluation Time on each business day and will adjust the Public Offering Price\nof the Units according to this valuation. This Public Offering Price will be effective for all orders received before the Evaluation Time\non each such day. If we or the Trustee receive orders for purchases, sales or redemptions after that time, or on a day which is not a\nbusiness day, they will be held until the next determination of price. The term “business day” as used in this prospectus\nshall mean any day on which the NYSE is open. For purposes of Securities and Unit settlement, the term business day does not include days\non which U.S. financial institutions are closed.

The aggregate underlying value of the Securities\nin the Trust will be determined as follows: if the Securities are listed on a national or foreign securities exchange or Nasdaq, Inc.,\ntheir value shall generally be based on the closing sale price on the exchange or system which is the principal market therefore (“Primary\nExchange”), which shall be deemed to be the NYSE if the Securities are listed thereon (unless the Sponsor deems such price inappropriate\nas the basis for evaluation). In the event a closing sale price on the Primary Exchange is not published, the Securities will be valued\nbased on the last trade price on the Primary Exchange. If no trades occur on the Primary Exchange for a specific trade date, the value\nwill be based on the closing sale price from, in the opinion of the Sponsor, an appropriate secondary exchange, if any. If no trades occur\non the Primary Exchange or any appropriate secondary exchange on a specific trade date, the Sponsor will determine the value of the Securities\nusing the best information available to the Sponsor, which may include the prior day’s evaluated price. If the Security is an American\nDepositary Receipt/ADR, Global Depositary Receipt/GDR or other similar security in which no trade occurs on the Primary Exchange or any\nappropriate secondary exchange on a specific trade date, the value will be based on the evaluated price of the underlying security, determined\nas set forth above, after applying the appropriate ADR/GDR ratio, the exchange rate and such other information which the Sponsor deems\nappropriate. For purposes of valuing Securities traded on Nasdaq, Inc., closing sale price shall mean the Nasdaq^® Official\nClosing Price as determined by Nasdaq, Inc. If the Securities are not so listed or, if so listed and the principal market therefore is\nother than on the Primary Exchange or any appropriate secondary exchange, the value shall generally be based on the current ask price\non the over-the-counter market (unless the Sponsor deems such price inappropriate as a basis for evaluation). If current ask prices are\nunavailable, the value is generally determined (a) on the basis of current ask prices for comparable securities, (b) by appraising\nthe value of the Securities on the ask side of the market, or (c) any combination of the above. If such prices are in a currency\nother than U.S. dollars, the value of such Security shall be converted to U.S. dollars based on current exchange rates (unless the Sponsor\ndeems such prices inappropriate as a basis for evaluation). If the Sponsor deems a price determined as set forth above to be inappropriate\nas the basis for evaluation, the Sponsor shall use such other information available to the Sponsor which it deems appropriate as the basis\nfor determining the value of a Security.

After the initial offering period is over,\nthe aggregate underlying value of the Securities will be determined as set forth above, except that bid prices are used instead of ask\nprices when necessary.

\n \n \n

Distribution of Units

We intend to qualify Units of the Trust\nfor sale in a number of states. All Units will be sold at the then current Public Offering Price.

The Sponsor compensates intermediaries,\nsuch as broker/dealers and banks, for their activities that are intended to result in sales of Units of the Trust. This compensation includes\ndealer concessions described in the following section and may include additional concessions and other compensation and benefits to broker/dealers\nand other intermediaries.

Dealer Concessions.

Dealers and other selling agents can purchase\nUnits at prices which represent a concession or agency commission of 2.00% of the Public Offering Price per Unit, subject to reductions\nset forth in “Public Offering—Discounts for Certain Persons.”

Eligible dealer firms and other selling\nagents who, during the previous consecutive 12-month period through the end of the most recent month, sold primary market units of unit\ninvestment trusts sponsored by us in the dollar amounts shown below will be entitled to up to the following additional sales concession\non primary market sales of units during the current month of unit investment trusts sponsored by us:

\n\n \n \n\n \n \n\n \n \n\n \n \n\n \n \n\n \n \n\n \n \n\n \n \n

Total sales\t (in millions) \t \t\t	Additional \nConcession
$25 but less than $100\t		0.035	%
$100 but less than $150\t		0.050	%
$150 but less than $250\t		0.075	%
$250 but less than $1,000\t		0.100	%
$1,000 but less than $5,000\t		0.125	%
$5,000 but less than $7,500\t		0.150	%
$7,500 or more\t		0.175	%

Dealers\nand other selling agents will not receive a concession on the sale of Units which are not subject to a transactional sales charge, but\nsuch Units will be included in determining whether the above volume sales levels are met. Eligible dealer firms and other selling agents\ninclude clearing firms that place orders with First Trust and provide First Trust with information with respect to the representatives\nwho initiated such transactions. Eligible dealer firms and other selling agents will not include firms that solely provide clearing services\nto other broker/dealer firms or firms who place orders through clearing firms that are eligible dealers. We reserve the right to change\nthe amount of concessions or agency commissions from time to time. Certain commercial banks may be making Units of the Trust available\nto their customers on an agency basis. A portion of the transactional sales charge paid by these customers is kept by or given to the\nbanks in the amounts shown above.

Other Compensation and Benefits to Broker/Dealers.

The\nSponsor, at its own expense and out of its own profits, currently provides additional compensation and benefits to broker/dealers who\nsell Units of this Trust and other First Trust products. This compensation is intended to result in additional sales of First Trust products\nand/or compensate broker/dealers and financial advisors for past sales. A number of factors are considered in determining whether to pay\nthese additional amounts. Such factors may include, but are not limited to, the level or type of services provided by the intermediary,\nthe level or expected level of sales of First Trust products by the intermediary or its agents, the placing of First Trust products on\na preferred or recommended product list, access to an intermediary’s personnel, and other factors. The Sponsor makes these payments\nfor marketing, promotional or related expenses, including, but not limited to, expenses of entertaining retail customers and financial\nadvisors, advertising, sponsorship of events or seminars, obtaining information about the breakdown of unit sales among an intermediary’s\nrepresentatives or offices, obtaining shelf space in broker/dealer firms and similar activities designed to promote the sale of the Sponsor’s\nproducts. The Sponsor makes such payments to a substantial majority of intermediaries that sell First Trust products. The Sponsor may\nalso make certain payments to, or on behalf of, intermediaries to defray a portion of their costs incurred for the purpose of facilitating\nUnit sales, such as the costs of developing or purchasing trading systems to process Unit trades. Payments of such additional compensation\ndescribed in this and the preceding paragraph, some of which may be characterized as “revenue sharing,” create a conflict\nof interest by influencing financial intermediaries and their agents to sell or recommend a First Trust product, including the Trust,\nover products offered by other sponsors or fund companies. These arrangements will not change the price you pay for your Units.

Advertising and Investment Comparisons.

Advertising\nmaterials regarding the Trust may discuss several topics, including: developing a long-term financial plan; working with your financial\nprofessional; the nature and risks of various investment strategies and unit investment trusts that could help you reach your financial\ngoals; the importance of discipline; how the Trust operates; how securities are selected; various unit investment trust features such\nas convenience and costs; and options available for certain types of unit investment trusts. These materials may include descriptions\nof the principal businesses of the companies represented in the Trust, research analysis of why they were selected and information relating\nto the qualifications of the persons or entities providing the research analysis. In addition, they may include research opinions on the\neconomy and industry sectors included and a list of investment products generally appropriate for pursuing those recommendations.

From\ntime to time we may compare the estimated returns of the Trust (which may show performance net of the expenses and charges the Trust would\nhave incurred) and returns over specified periods of other similar trusts we sponsor in our advertising and sales materials, with (1)\nreturns on other taxable investments such as the common stocks comprising various market indexes, corporate or U.S. Government bonds,\nbank CDs and money market accounts or funds, (2) performance data from Morningstar, Inc. or (3) information from publications such\nas Money, The New York Times, U.S. News and World Report, Bloomberg Businessweek, Forbes or Fortune.\nThe investment characteristics of the Trust differ from other comparative investments. You should not assume that these performance comparisons\nwill be representative of the Trust’s future performance. We may also, from time to time, use advertising which classifies trusts\nor portfolio securities according to capitalization and/or investment style.

\n \n \n

The Sponsor’s Profits

We\nwill receive a gross sales commission equal to the maximum transactional sales charge per Unit less any reduction as stated in “Public\nOffering.” We will also receive the amount of any collected creation and development fee. Also, any difference between our cost\nto purchase the Securities and the price at which we sell them to the Trust is considered a profit or loss (see Note 2 of “Notes\nto Schedule of Investments”). During the initial offering period, dealers and others may also realize profits or sustain losses\nas a result of fluctuations in the Public Offering Price they receive when they sell the Units.

In\nmaintaining a market for the Units, any difference between the price at which we purchase Units and the price at which we sell or redeem\nthem will be a profit or loss to us.

\n \n \n

The Secondary Market

Although\nnot obligated, we may maintain a market for the Units after the initial offering period and continuously offer to purchase Units at prices\nbased on the Redemption Price per Unit.

We\nwill pay all expenses to maintain a secondary market, except fees to value Trust Securities and Trustee costs to transfer and record the\nownership of Units. We may discontinue purchases of Units at any time. If you wish to dispose of your Units, you should ask us for\nthe current market prices before making a tender for redemption to the Trustee. If you sell or redeem your Units before you have paid\nthe total deferred sales charge on your Units, you will have to pay the remainder at that time.

\n \n \n

How We Purchase Units

The\nTrustee will notify us of any tender of Units for redemption. If our bid at that time is equal to or greater than the Redemption Price\nper Unit, we may purchase the Units. You will receive your proceeds from the sale no later than if they were redeemed by the Trustee.\nWe may tender Units that we hold to the Trustee for redemption as any other Units. If we elect not to purchase Units, the Trustee may\nsell tendered Units in the over-the-counter market, if any. However, the amount you will receive is the same as you would have received\non redemption of the Units.

\n \n \n

Expenses and Charges

The\nestimated annual expenses of the Trust are listed under “Fee Table.” If actual expenses of the Trust exceed the estimate,\nthe Trust will bear the excess. The Trustee will pay operating expenses of the Trust from the Income Account of the Trust if funds are\navailable, and then from the Capital Account. The Income and Capital Accounts are non-interest-bearing to Unit holders, so the Trustee\nmay earn interest on these funds, thus benefiting from their use.

First\nTrust Advisors L.P., an affiliate of ours, acts as Portfolio Supervisor and will be compensated for providing portfolio supervisory services\nas well as bookkeeping and other administrative services to the Trust. In providing portfolio supervisory services, the Portfolio Supervisor\nmay purchase research services from a number of sources, which may include underwriters or dealers of the Trust. As Sponsor, we will be\ncompensated for providing evaluation services and we will receive brokerage fees when the Trust uses us (or an affiliate of ours) as agent\nin buying or selling Securities. As authorized by the Indenture, the Trustee may employ a subsidiary or affiliate of the Trustee to act\nas broker to execute certain transactions for the Trust. The Trust will pay for such services at standard commission rates.

The\nfees payable to the Sponsor, First Trust Advisors L.P. and the Trustee are based on the largest aggregate number of Units of the Trust\noutstanding at any time during the calendar year, except during the initial offering period, in which case these fees are calculated based\non the largest number of Units outstanding during the period for which compensation is paid. These fees may be adjusted for inflation\nwithout Unit holders’ approval, but in no case will the annual fees paid to us or our affiliates for providing services to all unit\ninvestment trusts be more than the actual cost of providing such services in such year.

As\nSponsor, we will receive a fee from the Trust for creating and developing the Trust, including determining the Trust’s objectives,\npolicies, composition and size, selecting service providers and information services and for providing other similar administrative and\nministerial functions. The “creation and development fee” is a charge of $.050 per Unit outstanding at the end of the initial\noffering period. The Trustee will deduct this amount from the Trust’s assets as of the close of the initial offering period. We\ndo not use this fee to pay distribution expenses or as compensation for sales efforts. This fee will not be deducted from your proceeds\nif you sell or redeem your Units before the end of the initial offering period.

In\naddition to the Trust’s operating expenses and those fees described above, the Trust may also incur the following charges:

•

All legal expenses of the Trustee according to its responsibilities under the Indenture;

•

The expenses and costs incurred by the Trustee to protect the Trust and your rights and interests\n(i.e., participating in litigation concerning a portfolio security) and the costs of indemnifying the Trustee;

•

Fees for any extraordinary services the Trustee performed under the Indenture;

•

Payment for any loss, liability or expense the Trustee incurred without negligence, bad faith\nor willful misconduct on its part, in connection with its acceptance or administration of the Trust;

•

Payment for any loss, liability or expenses we incurred without negligence, bad faith or willful\nmisconduct in acting as Sponsor of the Trust;

•

Foreign custodial and transaction fees (which may include compensation paid to the Trustee or\nits subsidiaries or affiliates), if any; and/or

•

All taxes and other government charges imposed upon the Securities or any part of the Trust.

The\nabove expenses and the Trustee’s annual fee are secured by a lien on the Trust. In addition, if there is not enough cash in the\nIncome or Capital Account, the Trustee has the power to sell Securities to make cash available to pay these charges which may result in\ncapital gains or losses to you. See “Tax Status.”

\n \n \n

Tax Status

Federal Tax Matters.

This\nsection discusses some of the main U.S. federal income tax consequences of owning Units of the Trust as of the date of this prospectus.\nTax laws and interpretations change frequently, and this summary does not describe all of the tax consequences to all taxpayers. For example,\nthis summary generally does not describe your situation if you are a broker/dealer or other investor with special circumstances. In addition,\nthis section may not describe your state, local or non-U.S. tax consequences.

This\nfederal income tax summary is based in part on the advice of counsel to the Sponsor. The Internal Revenue Service (“IRS”)\ncould disagree with any conclusions set forth in this section. In addition, our counsel may not have been asked to review, and may not\nhave reached a conclusion with respect to the federal income tax treatment of the assets to be deposited in the Trust. This summary may\nnot be sufficient for you to use for the purpose of avoiding penalties under federal tax law.

As\nwith any investment, you should seek advice based on your individual circumstances from your own tax advisor.

Trust Status.

Unit\ninvestment trusts maintain both Income and Capital Accounts, regardless of tax structure. Please refer to the “Income and Capital\nDistributions” section of the prospectus for more information.

The\nTrust intends to qualify as a “regulated investment company,” commonly known as a “RIC,” under the federal tax\nlaws. If the Trust qualifies as a RIC and distributes its income as required by the tax law, the Trust generally will not pay federal\nincome taxes. For federal income tax purposes, you are treated as the owner of the Trust Units and not of the assets held by the Trust.\n

Income from the Trust.

Trust\ndistributions are generally taxable. After the end of each year, you will receive a tax statement that separates the Trust’s distributions\ninto ordinary income dividends, capital gain dividends and return of capital. Income reported is generally net of expenses (but see “Treatment\nof Trust Expenses” below). Ordinary income dividends are generally taxed at your ordinary income tax rate, however, certain dividends\nreceived from the Trust may be taxed at the capital gains tax rates. Generally, all capital gain dividends are treated as long-term capital\ngains regardless of how long you have owned your Units. In addition, the Trust may make distributions that represent a return of capital\nfor tax purposes and will generally not be currently taxable to you, although they generally reduce your tax basis in your Units and thus\nincrease your taxable gain or decrease your loss when you dispose of your Units. The tax laws may require you to treat distributions made\nto you in January as if you had received them on December 31 of the previous year.

Some\ndistributions from the Trust may qualify as long-term capital gains, which, if you are an individual, is generally taxed at a lower rate\nthan your ordinary income and short-term capital gain income. The distributions from the Trust that you must take into account for federal\nincome tax purposes are not reduced by the amount used to pay a deferred sales charge, if any. Distributions from the Trust, including\ncapital gains, may also be subject to a “Medicare tax” if your adjusted gross income exceeds certain threshold amounts.

Certain Stock Dividends.

Ordinary\nincome dividends received by an individual Unit holder from a RIC such as the Trust are generally taxed at the same rates that apply to\nlong-term capital gains, provided certain holding period requirements are satisfied and provided the dividends are attributable to qualifying\ndividend income (“QDI”) received by the Trust itself. Dividends that do not meet these requirements will generally be taxed\nat ordinary income tax rates. After the end of the tax year, the Trust will provide a tax statement to its Unit holders reporting the\namount of any distribution which may be taken into account as a dividend which is eligible for the capital gains tax rates.

Unit\nholders that are corporations may be eligible for the dividends received deduction with respect to certain ordinary income dividends on\nUnits that are attributable to qualifying dividends received by the Trust from certain corporations.

Sale of Units.

If\nyou sell your Units (whether to a third party or to the Trust), you will generally recognize a taxable gain or loss. To determine the\namount of this gain or loss, you must subtract your (adjusted) tax basis in your Units from the amount you receive from the sale. Your\noriginal tax basis in your Units is generally equal to the cost of your Units, including sales charges. In some cases, however, you may\nhave to adjust your tax basis after you purchase your Units, in which case your gain would be calculated using your adjusted basis.

The\ntax statement you receive in regard to the sale or redemption of your Units may contain information about your basis in the Units and\nwhether any gain or loss recognized by you should be considered long-term or short-term capital gain. The information reported to you\nis based upon rules that do not take into consideration all of the facts that may be known to you or to your advisors. You should consult\nwith your tax advisor about any adjustments that may need to be made to the information reported to you in determining the amount of your\ngain or loss.

Distribution Reinvestment Option.

If\nyou elect to reinvest your distributions into additional Units, you will be treated as if you have received your distribution in an amount\nequal to the distribution you are entitled to. Your tax liability will be the same as if you received the distribution in cash. Also,\nthe reinvestment would generally be considered a purchase of new Units for federal income tax purposes.

Treatment of Trust Expenses.

Expenses\nincurred and deducted by the Trust will generally not be treated as income taxable to you. In some cases, however, you may be required\nto treat your portion of these Trust expenses as income. You may not be able to take a deduction for some or all of these expenses even\nif the cash you receive is reduced by such expenses.

Investments in Certain Non-U.S. Corporations.

A\nforeign corporation will generally be treated as a passive foreign investment company (“PFIC”) if 75% or more of its income\nis passive income or if 50% or more of its assets are held to produce passive income. If the Trust holds an equity interest in PFICs,\nthe Trust could be subject to U.S. federal income tax and additional interest charges on gains and certain distributions from the PFICs,\neven if all the income or gain is distributed in a timely fashion to the Trust Unit holders. The Trust will not be able to pass through\nto its Unit holders any credit or deduction for such taxes if the taxes are imposed at the Trust level. The Trust may be able to make\nan election that could limit the tax imposed on the Trust. In this case, the Trust would recognize as ordinary income any increase in\nthe value of such PFIC shares, and as ordinary loss any decrease in such value to the extent it did not exceed prior increases included\nin income.

Under\nthis election, the Trust might be required to recognize income in excess of its distributions from the PFICs and its proceeds from dispositions\nof PFIC stock during that year, and such income would nevertheless be subject to the distribution requirement and would be taken into\naccount for purposes of determining the application of the 4% excise tax imposed on RICs that do not meet certain distribution thresholds.\nDividends paid by PFICs are not treated as QDI to shareholders of the PFICs.

Non-U.S. Investors.

If\nyou are a non-U.S. investor, distributions from the Trust treated as dividends will generally be subject to a U.S. withholding tax of\n30% of the distribution. Certain dividends, such as capital gains dividends and short-term capital gains dividends, may not be subject\nto U.S. withholding taxes. In addition, some non-U.S. investors may be eligible for a reduction or elimination of U.S. withholding taxes\nunder a treaty. However, the qualification for those exclusions may not be known at the time of the distribution and some excluded income\nmay be taken into consideration for alternative minimum tax purposes.

Separately,\nthe United States, pursuant to the Foreign Account Tax Compliance Act (“FATCA”) imposes a 30% tax on certain non-U.S. entities\nthat receive U.S. source interest or dividends if the non-U.S. entity does not comply with certain U.S. disclosure and reporting requirements.\nThis FATCA tax also currently applies to the gross proceeds from the disposition of securities that produce U.S. source interest or dividends.\nHowever, proposed regulations may eliminate the requirement to withhold on payments of gross proceeds from dispositions.

It\nis the responsibility of the entity through which you hold your Units to determine the applicable withholding.

Foreign Tax Credit.

If\nthe Trust directly or indirectly invests in non-U.S. stocks, the tax statement that you receive may include an item showing foreign taxes\nthe Trust paid to other countries. You may be able to deduct or receive a tax credit for your share of these taxes. The Trust would have\nto meet certain IRS requirements in order to pass through credits to you.

In-Kind Distributions.

If\npermitted by this prospectus, as described in “Redeeming Your Units,” you may request an In-Kind Distribution of Trust assets\nwhen you redeem your Units. This distribution is subject to tax, and you will generally recognize gain or loss, generally based on the\nvalue at that time of the securities and the amount of cash received.

You\nshould consult your tax advisor regarding potential foreign, state or local taxation with respect to your Units.

\n \n \n

Retirement Plans

You\nmay purchase Units of the Trust for:

•

Individual Retirement Accounts;

•

Keogh Plans;

•

Pension funds; and

•

Other tax-deferred retirement plans.

Generally,\nthe federal income tax on capital gains and income received in each of the above plans is deferred until you receive distributions. These\ndistributions are generally treated as ordinary income but may, in some cases, be eligible for special averaging or tax-deferred rollover\ntreatment. Before participating in a plan like this, you should review the tax laws regarding these plans and consult your attorney or\ntax advisor. Brokerage firms and other financial institutions offer these plans with varying fees and charges.

\n \n \n

Rights of Unit Holders

Unit Ownership.

Ownership\nof Units will not be evidenced by certificates. If you purchase or hold Units through a broker/dealer or bank, your ownership of Units\nwill be recorded in book-entry form at the Depository Trust Company (“DTC”) and credited on its records to your broker/dealer’s\nor bank’s DTC account. Transfer of Units will be accomplished by book entries made by DTC and its participants if the Units are\nregistered to DTC or its nominee, Cede & Co. DTC will forward all notices and credit all payments received in respect of the Units\nheld by the DTC participants. You will receive written confirmation of your purchases and sales of Units from the broker/dealer or bank\nthrough which you made the transaction. You may transfer your Units by contacting the broker/dealer or bank through which you hold your\nUnits.

Unit Holder Reports.

The\nTrustee will prepare a statement detailing the per Unit amounts (if any) distributed from the Income Account and Capital Account in connection\nwith each distribution. In addition, at the end of each calendar year, the Trustee will prepare a statement which contains the following\ninformation:

•

A summary of transactions in the Trust for the year;

•

A list of any Securities sold during the year and the Securities held at the end of that year\nby the Trust;

•

The Redemption Price per Unit, computed on the 31st day of December of such year (or the last\nbusiness day before); and

•

Amounts of income and capital distributed during the year.

By\nFebruary 15th yearly, the Annual Reports are posted to the Sponsor’s website (www.ftportfolios.com) in the UIT Tax Center and retrievable\nby CUSIP. You may also request one be sent to you by calling the Sponsor at 800–621–1675, dept. code 2. In addition, you may\nalso request from the Trustee copies of the evaluations of the Securities as prepared by the Sponsor to enable you to comply with applicable\nfederal and state tax reporting requirements.

\n \n \n

Income and Capital Distributions

You will be eligible to receive distributions,\nif any, on your Units only after you become a Record Owner. The Trustee will credit dividends received on the Trust’s Securities\nto the Income Account of the Trust. All other receipts, such as return of capital or capital gain dividends, are credited to the Capital\nAccount of the Trust. Dividends received on foreign Securities, if any, are converted into U.S. dollars at the applicable exchange rate.

The Trustee will distribute money from\nthe Income Account, as determined at the semi-annual Income Account Distribution Record Date, semi-annually on the twenty-fifth day of\neach June and December to Unit holders of record on the tenth day of such months provided the amount equals at least $1.00 per 100 Units.\nNo Income Account distribution will be paid if accrued expenses of the Trust exceed amounts in the Income Account on the Income Account\nDistribution Dates. Distribution amounts will vary with changes in the Trust’s fees and expenses, in dividends received and with\nthe sale of Securities. The Trustee will distribute money in the Capital Account monthly on the twenty-fifth day of each month to Unit\nholders of record on the tenth day of such month if the amount available for distribution from that account equals at least $1.00 per\n100 Units. In any case, the Trustee may distribute funds in the Capital Account in December of each year to avoid imposition of any income\nor excise taxes on undistributed income in the Trust and will distribute funds as part of the final liquidation distribution.

If an Income or Capital Account distribution\ndate is a day on which the NYSE is closed, the distribution will be made on the next day the stock exchange is open. Distributions are\npaid to Unit holders of record determined as of the close of business on the Record Date for that distribution or, if the Record Date\nis a day on which the NYSE is closed, the first preceding day on which the exchange is open.

We anticipate that there will be enough\nmoney in the Capital Account of the Trust to pay the deferred sales charge to the Sponsor. If not, the Trustee may sell Securities to\nmeet the shortfall.

Within a reasonable time after the Trust\nis terminated, you will receive a pro rata share of the money from the sale of the Securities and amounts in the Income and Capital Accounts.\nAll Unit holders will receive a pro rata share of any other assets remaining in your Trust, after deducting any unpaid expenses.

The Trustee may establish reserves (the\n“Reserve Account”) within the Trust to cover anticipated state and local taxes or any governmental charges to be paid out\nof the Trust.

Distribution Reinvestment Option.\nYou may elect to have each distribution of income and/or capital reinvested into additional Units of the Trust by notifying your broker/dealer\nor bank within the time period required by such entities so that they can notify the Trustee of your election at least 10 days before\nany Record Date. Each later distribution of income and/or capital on your Units will be reinvested by the Trustee into additional Units\nof such Trust. There is no sales charge on Units acquired through the Distribution Reinvestment Option, as discussed under “Public\nOffering.” This option may not be available in all states. Each reinvestment plan is subject to availability or limitation by the\nSponsor and each broker/dealer or selling firm. The Sponsor or broker/dealers may suspend or terminate the offering of a reinvestment\nplan at any time. Because the Trust may begin selling Securities nine business days prior to the Mandatory Termination Date, reinvestment\nis not available during this period. Please contact your financial professional for additional information. Please note that even if\nyou reinvest distributions, they are still considered distributions for income tax purposes.

\n \n \n

Redeeming Your Units

You\nmay redeem all or a portion of your Units at any time by sending a request for redemption to your broker/dealer or bank through which\nyou hold your Units. No redemption fee will be charged, but you are responsible for any governmental charges that apply. Certain broker/dealers\nmay charge a transaction fee for processing redemption requests. One business day after the day you tender your Units (the “Date\nof Tender”) you will receive cash in an amount for each Unit equal to the Redemption Price per Unit calculated at the Evaluation\nTime on the Date of Tender.

The\nDate of Tender is considered to be the date on which your redemption request is received by the Trustee from the broker/dealer or bank\nthrough which you hold your Units (if such day is a day the NYSE is open for trading). However, if the redemption request is received\nafter 4:00 p.m. Eastern time (or after any earlier closing time on a day on which the NYSE is scheduled in advance to close at such earlier\ntime), the Date of Tender is the next day the NYSE is open for trading.

Any\namounts paid on redemption representing income will be withdrawn from the Income Account if funds are available for that purpose, or from\nthe Capital Account. All other amounts paid on redemption will be taken from the Capital Account.

If\nyou tender for redemption at least 2,500 Units, or such larger amount as required by your broker/dealer or bank, rather than receiving\ncash, you may elect to receive an In-Kind Distribution in an amount equal to the Redemption Price per Unit by making this request to your\nbroker/dealer or bank at the time of tender. However, to be eligible to participate in the In-Kind Distribution option at redemption,\nUnit holders must hold their Units through the end of the initial offering period. No In-Kind Distribution requests submitted during the\n10 business days prior to the Trust’s Mandatory Termination Date will be honored. Where possible, the Trustee will make an In-Kind\nDistribution by distributing each of the Securities in book-entry form to your bank’s or broker/dealer’s account at DTC. The\nTrustee will subtract any customary transfer and registration charges from your In-Kind Distribution. As a tendering Unit holder, you\nwill receive your pro rata number of whole shares of Securities that make up the portfolio, and cash from the Capital Account equal to\nthe fractional shares to which you are entitled.

If\nyou elect to receive an In-Kind Distribution of Securities, you should be aware that it will be considered a taxable event at the time\nyou receive the Securities. See “Tax Status” for additional information.

The\nTrustee may sell Securities to make funds available for redemption. If Securities are sold, the size and diversification of the Trust\nwill be reduced. These sales may result in lower prices than if the Securities were sold at a different time.

Your\nright to redeem Units (and therefore, your right to receive payment) may be delayed:

•

If the NYSE is closed (other than customary weekend and holiday closings);

•

If the SEC determines that trading on the NYSE is restricted or that an emergency exists making\nsale or evaluation of the Securities not reasonably practical; or

•

For any other period permitted by SEC order.

The\nTrustee is not liable to any person for any loss or damage which may result from such a suspension or postponement.

The Redemption Price.

The\nRedemption Price per Unit is determined by the Trustee by:

adding

cash in the Income and Capital Accounts of the Trust not designated to purchase Securities;

the aggregate underlying value of the Securities held in the Trust; and

dividends receivable on the Securities trading ex-dividend as of the date of computation; and

deducting

any applicable taxes or governmental charges that need to be paid out of the Trust;

any amounts owed to the Trustee for its advances;

estimated accrued expenses of the Trust, if any;

cash held for distribution to Unit holders of record of the Trust as of the business day before\nthe evaluation being made;

liquidation costs for foreign Securities, if any; and

other liabilities incurred by the Trust; and

dividing

the result by the number of outstanding Units of the Trust.

Any\nremaining deferred sales charge on the Units when you redeem them will be deducted from your redemption proceeds. In addition, until they\nare collected, the Redemption Price per Unit will include estimated organization costs as set forth under “Fee Table.”

\n \n \n

Removing Securities from the Trust

The\nportfolio of the Trust is not managed. However, we may, but are not required to, direct the Trustee to dispose of a Security in certain\nlimited circumstances, including situations in which:

•

The issuer of the Security defaults in the payment of a declared dividend;

•

Any action or proceeding prevents the payment of dividends;

•

There is any legal question or impediment affecting the Security;

•

The issuer of the Security has breached a covenant which would affect the payment of dividends,\nthe issuer’s credit standing, or otherwise damage the sound investment character of the Security;

•

The issuer has defaulted on the payment of any other of its outstanding obligations;

•

There has been a public tender offer made for a Security or a merger or acquisition is announced\naffecting a Security, and that in our opinion the sale or tender of the Security is in the best interest of Unit holders;

•

The sale of Securities is necessary or advisable (i) in order to maintain the qualification of the Trust as a “regulated investment\ncompany” in the case of the Trust which has elected to qualify as such or (ii) to provide funds to make any distribution for a taxable\nyear in order to avoid imposition of any income or excise taxes on undistributed income in the Trust which is a “regulated investment\ncompany”;

•

The price of the Security has declined to such an extent, or such other credit factors exist,\nthat in our opinion keeping the Security would be harmful to the Trust;

•

As a result of the ownership of the Security, the Trust or its Unit holders would be a direct\nor indirect shareholder of a passive foreign investment company; or

•

The sale of the Security is necessary for the Trust to comply with such federal and/or state\nlaws, regulations and/or regulatory actions and interpretations which may be in effect from time to time.

Except for instances in which the Trust\nacquires Replacement Securities, as described in “The FT Series,” the Trust will generally not acquire any securities or other\nproperty other than the Securities. The Trustee, on behalf of the Trust and at the direction of the Sponsor, will vote for or against\nany offer for new or exchanged securities or property in exchange for a Security, such as those acquired in a merger or other transaction.\nIf such exchanged securities or property are acquired by the Trust, at our instruction, they will either be sold or held in the Trust.\nIn making the determination as to whether to sell or hold the exchanged securities or property we may get advice from the Portfolio Supervisor.\nAny proceeds received from the sale of Securities, exchanged securities or property will be credited to the Capital Account of the Trust\nfor distribution to Unit holders or to meet redemption requests. The Trustee may retain and pay us or an affiliate of ours to act as agent\nfor the Trust to facilitate selling Securities, exchanged securities or property from the Trust. If we or our affiliate act in this capacity,\nwe will be held subject to the restrictions under the 1940 Act. When acting in an agency capacity, we may select various broker/dealers\nto execute securities transactions on behalf of the Trust, which may include broker/dealers who sell Units of the Trust. We do not consider\nsales of Units of the Trust or any other products sponsored by First Trust as a factor in selecting such broker/dealers. As authorized\nby the Indenture, the Trustee may also employ a subsidiary or affiliate of the Trustee to act as broker in selling such Securities or\nproperty. The Trust will pay for these brokerage services at standard commission rates.

The Trustee may sell Securities designated\nby us, or, absent our direction, at its own discretion, in order to meet redemption requests or pay expenses. In designating Securities\nto be sold, we will try to maintain the proportionate relationship among the Securities. If this is not possible, the composition and\ndiversification of the Trust may be changed.

\n \n \n

Amending or Terminating the Indenture

Amendments. The Indenture may be\namended by us and the Trustee without your consent:

•

To cure ambiguities;

•

To correct or supplement any defective or inconsistent provision;

•

To make any amendment required by any governmental agency; or

•

To make other changes determined not to be adverse to your best interests (as determined by us and the Trustee).

Termination. As provided by the\nIndenture, the Trust will terminate on the Mandatory Termination Date as stated in the “Summary of Essential Information.”\nThe Trust may be terminated earlier:

•

Upon the consent of 100% of the Unit holders of the Trust;

•

If the value of the Securities owned by the Trust as shown by any evaluation is less than the lower of $2,000,000 or 20% of the total\nvalue of Securities deposited in the Trust during the initial offering period (“Discretionary Liquidation Amount”); or

•

In the event that Units of the Trust not yet sold aggregating more than 60% of the Units of the Trust are tendered for redemption\nby underwriters, including the Sponsor.

If the Trust is terminated due to this\nlast reason, we will refund your entire sales charge; however, termination of the Trust before the Mandatory Termination Date for any\nother stated reason will result in all remaining unpaid deferred sales charges on your Units being deducted from your termination proceeds.\nFor various reasons, the Trust may be reduced below the Discretionary Liquidation Amount and could therefore be terminated before the\nMandatory Termination Date.

Unless\nterminated earlier, the Trustee may begin to sell Securities in connection with the termination of the Trust as early as nine business\ndays prior to, but will sell Securities no later than, the Mandatory Termination Date. We will determine the manner and timing of the\nsale of Securities. Because the Trustee must sell the Securities within a relatively short period of time, the sale of Securities as part\nof the termination process may result in a lower sales price than might otherwise be realized if such sale were not required at this time.

You\nwill receive a cash distribution from the sale of the remaining Securities, along with your interest in the Income and Capital Accounts,\nwithin a reasonable time after the Trust is terminated. The Trustee will deduct from the Trust any accrued costs, expenses, advances or\nindemnities provided for by the Indenture, including estimated compensation of the Trustee and costs of liquidation and any amounts required\nas a reserve to pay any taxes or other governmental charges.

\n \n \n

Information on the Sponsor and Trustee

The Sponsor.

We,\nFirst Trust Portfolios L.P., specialize in the underwriting, trading and wholesale distribution of unit investment trusts under the “First\nTrust” brand name as well as other securities. An Illinois limited partnership formed in 1991, we took over the First Trust product\nline and act as Sponsor for successive series of:

•

The First Trust Combined Series

•

FT Series (formerly known as The First Trust Special Situations Trust)

•

The First Trust Insured Corporate Trust

•

The First Trust of Insured Municipal Bonds

•

The First Trust GNMA

•

FTP Series

The\nFirst Trust product line commenced with the first insured unit investment trust in 1974. To date we have deposited more than $670 billion\nin First Trust unit investment trusts. Our employees include a team of professionals with many years of experience in the unit investment\ntrust industry.

We\nare a member of FINRA and SIPC. Our principal offices are at 120 East Liberty Drive, Wheaton, Illinois 60187; telephone number 800–621–1675.\nAs of December 31, 2025, the total partners’ capital of First Trust Portfolios L.P. was $125,781,225.

This\ninformation refers only to us and not to the Trust or to any series of the Trust or to any other dealer. We are including this information\nonly to inform you of our financial responsibility and our ability to carry out our contractual obligations. We will provide more detailed\nfinancial information on request.

Code\nof Ethics. The Sponsor and the Trust have adopted a code of ethics requiring the Sponsor’s employees who have access to information\non Trust transactions to report personal securities transactions. The purpose of the code is to avoid potential conflicts of interest\nand to prevent fraud, deception or misconduct with respect to the Trust.

The Trustee.

The\nTrustee is The Bank of New York Mellon, a trust company organized under the laws of New York. The Bank of New York Mellon has its unit\ninvestment trust division offices at 240 Greenwich Street, New York, New York 10286, telephone 800–813–3074. If you have questions\nregarding your account or your Trust, please contact the Trustee at its unit investment trust division offices or your financial advisor.\nThe Sponsor does not have access to individual account information. The Bank of New York Mellon is subject to supervision and examination\nby the Superintendent of the New York State Department of Financial Services and the Board of Governors of the Federal Reserve System,\nand its deposits are insured by the Federal Deposit Insurance Corporation to the extent permitted by law.

The\nTrustee has not participated in selecting the Securities; it only provides administrative services.

Limitations of Liabilities of Sponsor and Trustee.

Neither\nwe nor the Trustee will be liable for taking any action or for not taking any action in good faith according to the Indenture. We will\nalso not be accountable for errors in judgment. We will only be liable for our own willful misfeasance, bad faith, gross negligence (ordinary\nnegligence in the Trustee’s case) or reckless disregard of our obligations and duties. The Trustee is not liable for any loss or\ndepreciation when the Securities are sold. If we fail to act under the Indenture, the Trustee may do so, and the Trustee will not be liable\nfor any action it takes in good faith under the Indenture.

The\nTrustee will not be liable for any taxes or other governmental charges or interest on the Securities which the Trustee may be required\nto pay under any present or future law of the United States or of any other taxing authority with jurisdiction. Also, the Indenture states\nother provisions regarding the liability of the Trustee.

If\nwe do not perform any of our duties under the Indenture or are not able to act or become bankrupt, or if our affairs are taken over by\npublic authorities, then the Trustee may:

•

Appoint a successor sponsor, paying them a reasonable rate not more than that stated by the\nSEC;

•

Terminate the Indenture and liquidate the Trust; or

•

Continue to act as Trustee without terminating the Indenture.

The\nTrustee and Unit holders may rely on the accuracy of any evaluation prepared by the Sponsor. The Sponsor will make determinations in good\nfaith based upon the best available information, but will not be liable to the Trustee or Unit holders for errors in judgment.

\n \n \n

Other Information

Legal Opinions.

Our\ncounsel is Chapman and Cutler LLP, 320 S. Canal St., Chicago, Illinois 60606. They have passed upon the legality of the Units offered\nhereby and certain matters relating to federal tax law. Carter Ledyard & Milburn LLP acts as the Trustee’s counsel.

Experts.

The\nTrust’s statement of net assets, including the schedule of investments, as of the opening of business on the Initial Date of Deposit\nincluded in this prospectus, has been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated\nin their report appearing herein, and is included in reliance upon the report of such firm given upon their authority as experts in accounting\nand auditing.

Supplemental Information.

If\nyou write or call the Sponsor, you will receive free of charge supplemental information about this Series, which has been filed with the\nSEC and to which we have referred throughout. This information states more specific details concerning the nature, structure and risks\nof this product.

This\npage is intentionally left blank.

$\"\"$

Biotechnology Portfolio, Series 71
\nFT 13299

Sponsor:

$\"\"$

First Trust Portfolios L.P.

Member SIPC • Member FINRA
\n120 East Liberty Drive
\nWheaton, Illinois 60187
\n800–621–1675

Trustee:

The\nBank of New York Mellon

240\nGreenwich Street
\nNew York, New York 10286
\n800–813–3074
\n24-Hour Pricing Line:
\n800–446–0132

When\nUnits of the Trust are no longer available, this prospectus may be used as a preliminary prospectus
\nfor a future series, in which case you should note the following:

The\ninformation in the prospectus is not complete and may be changed. We may not sell, or accept offers to buy, securities of a future series\nuntil that series has become effective with the SEC. No securities can be sold in any state where a sale would be illegal.

This\nprospectus contains information relating to the above-mentioned unit investment trust, but does not contain all of the information about\nthis investment company as filed with the SEC in Washington, D.C. under the:

Securities\nAct of 1933 (file no. 333–298553) and

Investment\nCompany Act of 1940 (file no. 811–05903)

Information\nabout the Trust, including its Code of Ethics, can be reviewed and copied at the SEC’s Public Reference Room in Washington, D.C.\nInformation regarding the operation of the SEC’s Public Reference Room may be obtained by calling the SEC at 202–942–8090.

Information\nabout the Trust is available on the EDGAR Database on the SEC’s Internet site at www.sec.gov.

To obtain\ncopies at prescribed rates –

\tWrite:\tPublic Reference\nSection of the SEC
\n\t100 F Street, N.E.
\n\tWashington, D.C. 20549

October 30, 2026

PLEASE\nRETAIN THIS PROSPECTUS FOR FUTURE REFERENCE

$\"\"$

The FT Series

Information\nSupplement

This\nInformation Supplement provides additional information concerning the structure, operations and risks of the unit investment trust contained\nin FT 13299 not found in the prospectus for the Trust. This Information Supplement is not a prospectus and does not include all of the\ninformation you should consider before investing in the Trust. This Information Supplement should be read in conjunction with the prospectus\nfor the Trust in which you are considering investing.

This\nInformation Supplement is dated October 30, 2026. Capitalized terms have been defined in the prospectus.

Table\nof Contents

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

Risk Factors
Securities			1
Dividends			1
Biotechnology/Pharmaceutical			1
Foreign Issuers			2
Small and/or Mid Capitalization Companies			3
Concentration
Concentration Risk			3
Health Care			3

Risk Factors

Securities.\nAn investment in Units should be made with an understanding of the risks which an investment in common stocks entails, including the risk\nthat the financial condition of the issuers of the Securities or the general condition of the relevant stock market may worsen, and the\nvalue of the Securities and therefore the value of the Units may decline. Common stocks are especially susceptible to general stock market\nmovements and to volatile increases and decreases of value, as market confidence in and perceptions of the issuers change. These perceptions\nare based on unpredictable factors, including expectations regarding government, economic, monetary and fiscal policies, inflation and\ninterest rates, economic expansion or contraction, and global or regional political, economic or banking crises.

Dividends.\nShareholders of common stocks have rights to receive payments from the issuers of those common stocks that are generally subordinate to\nthose of creditors of, or holders of debt obligations or preferred stocks of, such issuers. Shareholders of common stocks have a right\nto receive dividends only when and if, and in the amounts, declared by the issuer’s board of directors and have a right to participate\nin amounts available for distribution by the issuer only after all other claims on the issuer have been paid or provided for. Common stocks\ndo not represent an obligation of the issuer and, therefore, do not offer any assurance of income or provide the same degree of protection\nof capital as do debt securities. The issuance of additional debt securities or preferred stock will create prior claims for payment of\nprincipal, interest and dividends which could adversely affect the ability and inclination of the issuer to declare or pay dividends on\nits common stock or the rights of holders of common stock with respect to assets of the issuer upon liquidation or bankruptcy. Cumulative\npreferred stock dividends must be paid before common stock dividends, and any cumulative preferred stock dividend omitted is added to\nfuture dividends payable to the holders of cumulative preferred stock. Preferred stockholders are also generally entitled to rights on\nliquidation which are senior to those of common stockholders.

Biotechnology/Pharmaceutical.\nAn investment in Units of the Trust should be made with an understanding of the problems and risks such an investment may entail.\nCompanies involved in advanced medical devices and instruments, drugs and biotechnology have potential risks unique to their sector of\nthe health care field. These companies are subject to governmental regulation of their products and services, a factor which could have\na significant and possibly unfavorable effect on the price and availability of such products or services. Furthermore, such companies\nface the risk of increasing competition from new products or services, new health care providers entering the marketplace, generic drug\nsales, the termination of patent protection for drug or medical supply products and the risk that technological advances will render their\nproducts obsolete. The research and development costs of bringing a drug to market are substantial, and include lengthy governmental review\nprocesses with no guarantee that the product will ever come to market. Many of these companies may have losses and may not offer certain\nproducts for several years. Such companies may also have persistent losses during a new product’s transition from development to\nproduction, and revenue patterns may be erratic.

As\nthe population of the United States ages, the companies involved in the biotechnology and pharmaceutical industries will continue to search\nfor and develop new drugs, medical products and medical services through advanced technologies and diagnostics. On a worldwide basis,\nbiotechnology and pharmaceutical companies are involved in the development and distributions of drugs, vaccines, medical products and\nmedical services. These activities may make the biotechnology/pharmaceuticals industries very attractive for investors seeking the potential\nfor growth in their investment portfolio. However, there are no assurances that the Trust’s objectives will be met.

Foreign\nIssuers. Since certain of the Securities held by the Trust consist of, or invest in, securities issued by foreign entities, an investment\nin the Trust involves certain investment risks that are different in some respects from an investment in a trust which invests solely\nin the securities of domestic entities. These investment risks include future political or governmental restrictions which might adversely\naffect the payment or receipt of payment of dividends on the relevant Securities, the possibility that the financial condition of the\nissuers of the Securities may become impaired or that the general condition of the relevant stock market may worsen (both of which would\ncontribute directly to a decrease in the value of the Securities and thus in the value of the Units), the limited liquidity and relatively\nsmall market capitalization of the relevant securities market, expropriation or confiscatory taxation, economic uncertainties and foreign\ncurrency devaluations and fluctuations. In addition, for foreign issuers that are not subject to the reporting requirements of the Securities\nExchange Act of 1934, as amended, there may be less publicly available information than is available from a domestic issuer. Also, foreign\nissuers are not necessarily subject to uniform accounting, auditing and financial reporting standards, practices and requirements comparable\nto those applicable to domestic issuers. The securities of many foreign issuers are less liquid and their prices more volatile than securities\nof comparable domestic issuers. In addition, fixed brokerage commissions and other transaction costs on foreign securities exchanges are\ngenerally higher than in the United States and there is generally less government supervision and regulation of exchanges, brokers and\nissuers in foreign countries than there is in the United States. However, due to the nature of the issuers of the Securities selected\nfor the Trust, the Sponsor believes that adequate information will be available to allow the Supervisor to provide portfolio surveillance\nfor the Trust.

Securities\nissued by non-U.S. issuers may pay interest and/or dividends in foreign currencies and may be principally traded in foreign currencies.\nTherefore, there is a risk that the U.S. dollar value of these interest and/or dividend payments and/or securities will vary with fluctuations\nin foreign exchange rates.

On\nthe basis of the best information available to the Sponsor at the present time, none of the Securities in the Trust are subject to exchange\ncontrol restrictions under existing law which would materially interfere with payment to the Trust of dividends due on, or proceeds from\nthe sale of, the Securities. However, there can be no assurance that exchange control regulations might not be adopted in the future which\nmight adversely affect payment to the Trust. The adoption of exchange control regulations and other legal restrictions could have an adverse\nimpact on the marketability of international securities in the Trust and on the ability of the Trust to satisfy its obligation to redeem\nUnits tendered to the Trustee for redemption. In addition, restrictions on the settlement of transactions on either the purchase or sale\nside, or both, could cause delays or increase the costs associated with the purchase and sale of the foreign Securities and correspondingly\ncould affect the price of the Units.

Investors\nshould be aware that it may not be possible to buy all Securities at the same time because of the unavailability of any Security, and\nrestrictions applicable to the Trust relating to the purchase of a Security by reason of the federal securities laws or otherwise.

Foreign\nsecurities generally have not been registered under the Securities Act of 1933 and may not be exempt from the registration requirements\nof such Act. Sales of non-exempt Securities by the Trust in the United States securities markets are subject to severe restrictions and\nmay not be practicable. Accordingly, sales of these Securities by the Trust will generally be effected only in foreign securities markets.\nAlthough the Sponsor does not believe that the Trust will encounter obstacles in disposing of the Securities, investors should realize\nthat the Securities may be traded in foreign countries where the securities markets are not as developed or efficient and may not be as\nliquid as those in the United States. The value of the Securities will be adversely affected if trading markets for the Securities are\nlimited or absent.

Small\nand/or Mid Capitalization Companies. While historically stocks of small and mid capitalization companies have outperformed the stocks\nof large companies, the former have customarily involved more investment risk as well. Such companies may have limited product lines,\nmarkets or financial resources; may lack management depth or experience; and may be more vulnerable to adverse general market or economic\ndevelopments than large companies. Some of these companies may distribute, sell or produce products which have recently been brought to\nmarket and may be dependent on key personnel.

The prices of small and\nmid cap company securities are often more volatile than prices associated with large company issues, and can display abrupt or erratic\nmovements at times, due to limited trading volumes and less publicly available information. Also, because such companies normally have\nfewer shares outstanding and these shares trade less frequently than large companies, it may be more difficult for the Trusts which contain\nthese Securities to buy and sell significant amounts of such shares without an unfavorable impact on prevailing market prices.

Concentration

Concentration Risk.\nWhen 25% or more of a trust’s portfolio is invested in securities issued by companies within a single sector, the trust is considered\nto be concentrated in that particular sector. A portfolio concentrated in one or more sectors may present more risks than a portfolio\nbroadly diversified over several sectors.

The\nTrust is concentrated in common stocks of companies within the health care sector.

Health\nCare. Health care companies include those involved in health care/managed care, hospital management/health services, the creation\nand development of drugs and biotechnology, and the development of advanced medical devices, instruments and other supplies, all of which\nhave unique potential risks. These companies are subject to governmental regulation of their products and services, a factor which could\nhave a significant and unfavorable effect on the price and availability of such products or services. Furthermore, such companies face\nthe risk of increasing competition from new products or services, generic drug sales, the termination of patent protection for drug or\nmedical supply products and the risk that technological advances will render their products obsolete. The research and development costs\nof bringing a drug to market are substantial, and include lengthy governmental review processes with no guarantee that the product will\never come to market. Many of these companies may have operating losses and may not offer certain products for several years. Such companies\nmay also have persistent losses during a new product’s transition from development to production, and revenue patterns may be erratic.\nOn a worldwide basis, such companies are involved in the development and distributions of drugs, vaccines, medical products and medical\nservices.

As\nthe number of older people in the United States increases, the health care system is increasingly burdened by the costs related to chronic\nillnesses, injuries, disabilities, nursing home care and home health care. These costs may be exaggerated for health care facility operators\nwho may already be burdened by events and conditions including fluctuating demand for services, the ability of the facility to provide\nthe services required, physicians’ confidence in the facility, management capabilities, competition with other hospitals, efforts\nby insurers and governmental agencies to limit rates, legislation establishing state rate-setting agencies, expenses, government regulation,\nthe cost and possible unavailability of malpractice insurance and the termination or restriction of governmental financial assistance,\nincluding that associated with Medicare, Medicaid and other similar third party programs. The challenges presented by an increase in the\nelderly population may require an increase in spending to improve and expand the health care infrastructure as well as overall reform\nto the entire health care system.

Legislative\nproposals concerning health care are proposed in Congress from time to time. These proposals span a wide range of topics, including cost\nand price controls (which may include a freeze on the prices of prescription drugs), national health insurance, incentives for competition\nin the provision of health care services, tax incentives and penalties related to health care insurance premiums and promotion of pre-paid\nhealth care plans. The long-term effects of any such proposals on the health care sector remain uncertain and cannot be predicted.

Undertaking

Subject to the\nterms and conditions of Section 15(d) of the Securities Exchange Act of 1934, the undersigned registrant hereby undertakes to file with\nthe Securities and Exchange Commission such supplementary and periodic information, documents, and reports as may be prescribed by any\nrule or regulation of the Commission heretofore or hereafter duly adopted pursuant to authority conferred in that section.

CONTENTS\nOF REGISTRATION STATEMENT

Bonding Arrangements of Depositor:

First Trust Portfolios\nL.P. is covered by a Brokers’ Fidelity Bond, in the total amount of $2,000,000, the insurer being National Union Fire Insurance\nCompany of Pittsburgh.

This Registration Statement on Form S-6 comprises the following papers and documents:

The Facing Sheet

The Prospectus

The Signatures

Exhibits

S-1

SIGNATURES

The Registrant,\nFT 13299, hereby identifies The First Trust Special Situations Trust, Series 4; The First Trust Special Situations Trust, Series 18; The\nFirst Trust Special Situations Trust, Series 69; The First Trust Special Situations Trust, Series 108; The First Trust Special Situations\nTrust, Series 119; The First Trust Special Situations Trust, Series 190; FT 286; The First Trust Combined Series 272; FT 412; FT 438;\nFT 556; FT 754; FT 1102; FT 1179; FT 2935; FT 3320; FT 3367; FT 3370; FT 3397; FT 3398; FT 3400; FT 3451; FT 3480; FT 3529; FT 3530; FT\n3568; FT 3569; FT 3570; FT 3572; FT 3615; FT 3647; FT 3650; FT 3689; FT 3690; FT 3729; FT 3780; FT 3940; FT 4020; FT 4037; FT 4143; FT\n4260; FT 4746; FT 4789; FT 5039; FT 5415; FT 7033; FT 7256; FT 7935; FT 8495; FT 8669; FT 8713; FT 8740; FT 8746; FT 8758; FT 8817; FT\n8955; FT 8956; FT 8965; FT 8976; FT 8978; FT 8993; FT 8994; FT 8997; FT 9039; FT 9040; FT 9042; FT 9058; FT 9068; FT 9203; FT 9204; FT\n9303; FT 9305; FT 9326; FT 9327; FT 9372; FT 9401; FT 9402; FT 9403; FT 9474; FT 9513; FT 9514; FT 9611; FT 9630; FT 9709; FT 9872; FT\n9908; FT 9911; FT 9923; FT 9937; FT 9950; FT 9961; FT 9977; FT 9978; FT 10051; FT 10057; FT 10105; FT 10109; FT 10121; FT 10272; FT 10295;\nFT 10323; FT 10412; FT 10447; FT 10455; FT 10475; FT 10528; FT 10583; FT 10689; FT 10694; FT 10756; FT 10865; FT 10895; FT 10976; FT 11035;\nFT 11095; FT 11096; FT 11097; FT 11155; FT 11156; FT 11223; FT 11224; FT 11285; FT 11462; FT 11475; FT 11642; FT 11756; FT 11909; FT 12152;\nFT 12153; FT 12155; FT 12399; FT 12415; FT 12445; FT 12508; FT 12545; FT 12583; FT 12718; FT 12728; FT 12832; FT 12883; FT 12889; FT 12902;\nFT 13043; FT 13045; FT 13168; FT 13221; FT 13307 and FT 13337 for purposes of the representations required by Rule 487 and represents\nthe following:

(1)that\nthe portfolio securities deposited in the series with respect to which this Registration Statement is being filed do not differ materially\nin type or quality from those deposited in such previous series;

(2)that,\nexcept to the extent necessary to identify the specific portfolio securities deposited in, and to provide essential financial information\nfor, the series with respect to the securities of which this Registration Statement is being filed, this Registration Statement does not\ncontain disclosures that differ in any material respect from those contained in the registration statements for such previous series as\nto which the effective date was determined by the Commission or the staff; and

(3)that\nit has complied with Rule 460 under the Securities Act of 1933.

Pursuant to\nthe requirements of the Securities Act of 1933, the Registrant, FT 13299, has duly caused this Amendment to the Registration Statement\nto be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Wheaton and State of Illinois on October 30,\n2026.

FT 13299

By:

First Trust Portfolios L.P.
\nDepositor

By:

/s/ Ronda L. Saeli-Chiappe
\nSenior Vice President

S-2

Pursuant to the requirements\nof the Securities Act of 1933, this Amendment to the Registration Statement has been signed below by the following person in the capacity\nand on the date indicated:

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

Name	Title*	Date

James A. Bowen	Director of The Charger Corporation, the General Partner of First Trust Portfolios L.P., and Chief Executive Officer of First Trust Portfolios L.P.	\n ) \n ) \n ) \n )By:/s/ Ronda L. Saeli-Chiappe \n ) Attorney-in-Fact** \n ) October 30, 2026 \n ) \n )
James M. Dykas	Chief Financial Officer of First Trust Portfolios L.P.	\n ) \n ) \n )
Christina Knierim	Controller of First Trust Portfolios L.P.	) \n)

The title of the person named herein represents his or her capacity in and relationship to First Trust\nPortfolios L.P., the Depositor.

Executed copies of the related powers of\nattorney were filed with the Securities and Exchange Commission in connection with the Amendment No. 1 to Form S-6 of FT 12910 (File\nNo. 333-294321) and the same is hereby incorporated herein by this reference.

S-3

CONSENT\nOF COUNSEL

The consent of counsel\nto the use of its name in the Prospectus included in this Registration Statement is contained in its opinion filed as Exhibit 3.1 of the\nRegistration Statement.

Consent\nof Independent Registered Public Accounting Firm

The consent of Deloitte & Touche LLP\nto the use of its name in the Prospectus included in the Registration Statement is filed as Exhibit 4.1 to the Registration Statement.

S-4

EXHIBIT\nINDEX

1.1

Standard Terms\nand Conditions of Trust for FT 10292 and certain subsequent Series, effective September 7, 2022 among First Trust Portfolios L.P.,\nas Depositor, The Bank of New York Mellon, as Trustee and First Trust Advisors L.P., as Portfolio Supervisor (incorporated by reference\nto Amendment No. 1 to Form S-6 [File No. 333-266325] filed on behalf of FT 10292).

1.1.1

Trust Agreement for FT 13299, effective October 30, 2026 among First Trust Portfolios L.P., as Depositor,\nThe Bank of New York Mellon, as Trustee and First Trust Advisors L.P., as Portfolio Supervisor.

1.2

Certificate\nof Limited Partnership of Nike Securities, L.P., predecessor of First Trust Portfolios L.P. (incorporated by reference to Amendment\nNo. 1 to Form S-6 [File No. 333-230481] filed on behalf of FT 8001).

1.3

Amended and\nRestated Limited Partnership Agreement of Nike Securities, L.P., predecessor of First Trust Portfolios L.P. (incorporated by reference\nto Amendment No. 1 to Form S-6 [File No. 333-230481] filed on behalf of FT 8001).

1.4

Articles of\nIncorporation of Nike Securities Corporation, predecessor to The Charger Corporation, the general partner of First Trust Portfolios\nL.P., Depositor (incorporated by reference to Amendment No. 1 to Form S-6 [File No. 333-230481] filed on behalf of FT 8001).

1.5

By-Laws of\nThe Charger Corporation, the general partner of First Trust Portfolios L.P., Depositor (incorporated by reference to Amendment No. 2 to\nForm S-6 [File No. 333-169625] filed on behalf of FT 2669).

1.7

Fund of Funds Agreements (incorporated by reference to Amendment No. 1 to Form S-6 [File No. 333-261661]\nfiled on behalf of FT 9909, Amendment No.\n1 to Form S-6 [File No. 333-261297] filed on behalf of FT\n9857, Amendment No. 1 to Form S-6 [File No. 333-262164] filed on behalf of FT\n9948, Amendment No. 1 to Form S-6 [File No. 333-262344] filed on behalf of FT\n9965, Amendment No. 1 to Form S-6 [File No. 333-263845] filed on behalf of FT\n10083 and Amendment No. 1 to Form S-6 [File No. 333-274281] filed on behalf of FT\n11028).

2.2

Code of\nEthics (incorporated by reference to Amendment No. 1 to Form S-6 [File No. 333-224320] filed on behalf of FT 7359).

S-5

3.1

Opinion of counsel as to legality of securities being registered.

4.1

Consent of Independent Registered Public Accounting Firm.

6.1

List of\nPrincipal Officers of the Depositor (incorporated by reference to Amendment No. 1 to Form S-6 [File No. 333-236093] filed on behalf\nof FT 8556).

7.1

Powers of Attorney\nexecuted by the Officers listed on page S-3 of this Registration Statement (incorporated by reference to Amendment No. 1 to Form S-6 [File\nNo. 333-294321] filed on behalf of FT 12910).

S-6

","zhKind","complete","公司与财报","行业与主题","aihot","/items/mxri2xs43zft2cjf2wvdcbcjy","https://www.sec.gov/Archives/edgar/data/2147133/000144554626008330/0001445546-26-008330-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1794614400&sig=ca89c39e6b9a6d38","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1794614400&sig=5d27167dd6d2e297 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1794614400&sig=d897b72a6d56d12e 96w","changelogVersion","2026-10-01T08:00"]